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ABSTRACT

CYCLIN E INDUCTION AND ONCOLYTIC REPLICATION OF E1B-DELETED
ADENOVIRUSES
Pei-Hsin Cheng
November 22, 2013

Virus-mediated oncolysis has been considered as a new and promising cancer
therapeutic approach. Although adenoviruses (Ads) with deletion of E1b55K
preferentially replicate in cancer cells and have been used in numerous cancer
treatments, the selective replication mechanism of this kind of virus still remains
controversial. The lack of a well-established studies focusing on possible
mechanisms enabling tumor selectivity of oncolytic Ads has hindered the further
development of virotherapies and limits their clinical applications. Therefore,
uncovering the molecular basis behind the tumor-killing phenomena will fill critical
gaps in our understanding of the oncolytic adenovirology. Previously our
laboratory has demonstrated that Ad E1B55K protein is involved in cyclin E
induction that is required for efficient virus replication. However, functional
E1B55K expression is not required for oncolytic Ad replication in cancer cells,
many of which have deregulated cyclin E overexpression. In this dissertation we
advanced the previous findings to further develop the mechanism model of
selective oncolytic replication of E1b-deleted Ads, and then applied these insights
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to design a novel tumor-specific oncolytic Ad vector. We demonstrated that
Ad-induced cyclin E subsequently activates CDK2 that targets the transcriptional
suppressor pRb to generate a cellular environment for productive viral replication.
Based on this understanding, a novel tumor-specific oncolytic vector, Ad-cycE,
was developed in which the cyclin E promoter was used to control a critical
regulatory viral E1a gene. As cyclin E is greatly induced in cancer cells after Ad
transduction, Ad-cycE shows significant oncolytic efficacy in vitro and strongly
repressed tumor growth in vivo. Additional work has been completed exploring the
impact of using a combination treatment of Ad-cycE and rapamycin which induces
autophagy; the results indicated a synergistic antitumor effect that was statistically
significant. This work has advanced our knowledge of the cancer selectivity of
E1b-deleted Ads, and will lead to further progress in the field of oncolytic
virotherapy.
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CHAPTER I
GENERAL INTRODUCTION

1.1. Oncolytic virotherapy
Cancer is the most common cause of death in the world (1). The limitations of
currently available therapies demand the continued development of more potent
cancer treatment options. Oncolytic virotherapy represents a fast growing
therapeutic platform for cancer treatment (2, 3). The therapeutic effects emanate
from a relatively small amount of virus, which preferentially replicates in and lyses
cancer cells. This is followed by a localized spread to the surrounding tumor cells,
ultimately leading to reduction of the tumor mass (4). Current oncolytic viruses,
including adenovirus (Ad), herpes simplex virus, measles virus, newcastle
disease virus, reovirus, parovirus, poliovirus, seneca valley virus, retrovirus,
vaccinia, and vesicular stomatitis virus, have been tested in numerous preclinical
or clinical settings (5). Although many viruses have already been developed, Ads
are still the most commonly used oncolytic vectors for gene therapy due to their
infection efficacy, high titer production, safety, easy genetic modification and
well-studied replication characteristics (6).

1.2. Human adenovirus
Human adenoviruses, as a common cause of respiratory tract diseases, are
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nonevenloped DNA viruses which can infect cells at many different cell cycle
stages without integrating into host cellular chromosomes (7). Adenovirus
serotype 5 (group C) have been wildely used in oncolytic virotherapy due to the
favorable safety profile and only cause clinical disease in patients by producing
negligible flu-like symptoms such as fever, myalgias, asthenia and chills (8, 18).
Generalized Ad structure and viral genome map were depicted in Figure 1.1. The
viral genome is composed of a linear, double-stranded DNA of approximately 36
Kb and can be divided into early (E) and late (L) genes (7, 9). The E1 genes
encode critical proteins including E1a and E1b for the initiation and regulation of
viral and cellular gene expression. The E2 genes encode three different proteins
which function directly in viral DNA replication, while the E3 genes encode
proteins which can modulate infected host immune responses. Products of the E4
genes encode proteins of diverse functions such as regulating viral gene
transcription, translation, mRNA nuclear export and apoptosis pathways. The L
genes encode structural proteins for packaging the viral genome into virion
particles during the final stages of virus replication.
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Figure 1.1. Generalized structure and genome map of adenovirus serotype 5.
Major structural components of a wild-type Ad capsid include hexon, penton base,
and fiber structures. Adenovirus capsids enclose a 36 Kb double-stranded DNA
genome, shown as the red line inside the capsids. The inverted terminal repeat
(ITR), the packaging signal (Ψ) and major late promoter (MLP) are indicated. The
solid lines represent viral genome and the white line represents the deleted region.
Early transcripts are represented by E1-E4 regions and late transcripts are
represented by L1-L5 regions. E1 region contains E1A and E1B regions. The
E1B19K and E1B55K in E1B region have a small overlap.
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The Ad infection begins by binding of knob domain on the adenovirus fiber to a
specific coxsackievirus and adenovirus receptor (CAR) located on the cell surface;
this interaction facilitates the entry of virus into the host cells by endocytosis. The
low-pH environment of the endosome allows the viral capsid to disassociate,
resulting in the release of virions from the endosome (10-12). By cooperating with
microtubules, virions are then transported to the nuclear pore complex where the
virions disassemble and the double-stranded viral DNA is released to directly
enter the nucleus.

The replication of Ads relies on utilizing the cellular components as building blocks.
The replication cycle of Ads is divided into two phases based on the onset of viral
gene expression (7). The early phase includes the expression of a set of viral
genes to promote cellular entry into an S-like phase, block apoptosis, and prevent
cellular immune responses. After the early gene products adjust the replication
machinery and other critical cellular components inside host cells, the gene
expression transitions to the late phase, in which adenoviral DNA replicates and
the structural proteins are synthesized. Once adenoviruses have finished the
amplification of their DNA and synthesis of their structural proteins, then viral
assembly can take place producing virions. Viral replication subsequently cause
cell lysis and release of progeny virions from the infected cells, leading to
significant amplification of the Ads which produces up to 10,000 viral particles per
cell (7, 13).
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1.3. E1b55K-deleted oncolytic adenoviruses
The idea of treating cancers with the adenoviruses began in the 1950s (5, 14).
Wild-type Ad5 was injected in thirty patients with epidermoid cervical carcinomas
and 65% of the virus injections induced necrosis in the tumors without causing
severe toxicity. While producing some promising results, the long-term safety
concerns, limited final therapeutic efficacy and tumor recurrence after the
treatment was completed prevented further development of this approach until
recently. A novel gene-attenuated oncolytic adenovirus dl1520 (ONYX-015) was
designed with an 827-bp deletion in the E1b region and a point mutation which
generates a premature stop codon to prevent the expression of its E1B55K
protein (Fig 1.1) (15-17). This new virus dl1520 showed potent and promising
oncolytic efficacy in several preclinical studies and became the first oncolytic
adenovirus used in the clinical trials in United States since 1996, treating
approximately 200-300 cancer patients with various routes of administration in
more than ten clinical trials (from phase I to II) (17, 18). However, during a phase
III clinical trial in 2003, when treatment with dl1520 was combined with
chemotherapy in patients with head and neck squamous cell carcinoma the trial
was suspended due to limited therapeutic potential in metastatic cancer patients
(18).

H101 (Oncorine) is another oncolytic adenovirus similar to dl1520 generated by
the Chinese company, Sunway Biotech (18, 19). The phase I clinical trial with
H101 as a single therapeutic agent began in 2000 in China and the phase II and
III trials of H101 in combination with chemotherapy started from 2001 to 2004.
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Overall, the clinical tolerability and responses of H101 treatment have been very
promising (18, 19). The rights to dl1520 were bought by Sunway Biotech which
has completed Phase III clinical studies. More than 600 cancer patients have
safely received the treatment with H101 in clinical trials in China (18, 20). The
company reported a 79% positive response rate for H101 plus chemotherapy as
compared with 40% for chemotherapy alone (21). Considering the impact of these
results, the Chinese State Food and Drug Administration approved H101 for use
in combination with chemotherapy for the treatment of late-stage cancers.
Therefore, Sunway Biotech has marketed H101 for treating head and neck
cancers (21, 22). Besides H101, this company has also developed other
genetically modified oncolytic adenoviruses H102 and H103 for cancer treatment
(23). H102 virus replication is driven by the alpha-fetoprotein promoter which
specifically targets primary hepatocellular carcinoma, and is currently in the
preclinical stage of development. H103 is an oncolytic adenovirus carrying a
tumor antigen known as heat shock protein (HSP) 70 gene which can stimulate an
antitumor immune response while the virus selectively replicates within tumor
cells. A phase I clinical trial of intratumoral injection of H103 has been conducted
in a total of 27 patients with advanced stage solid tumors; an 11.1% objective
response (cases with complete response + partial response) to H103-injected
tumors and a 48.1% clinical benefit rate (cases with complete response + partial
response + minor response + maintain a stable disease) was reported in 2008
(20).
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Currently various oncolytic adenoviruses have been reported in preclinical studies
and at least ten of these have been active or approved for human clinical trials (3,
5). Examples include Ad-OC-E1a (24), Ad5-CD/TKrep (25, 26), Ad-delta24-RGD
(27, 28), CG7060 (CV706) (29), CG7870 (CV787) (30), CG0070 (31), Telomelysin
(OBP-301) (32), CGTG-102 (33), H103 (20), KH901 (34) and ICOVIR-5 (currently
recruiting patients, Clinicaltrials.gov identifier: NCT01864759). These vectors
were constructed based on the deletion of critical viral genes combined with
multiple strategies such as transcriptionally targeting cancer cells with
tumor-specific promoters, or transductionally targeting cancers with modification
on various viral capsid proteins, or arming the vectors with immune stimulating
genes (35). Nevertheless H101 is the only oncolytic adenovirus that has been
commercially approved for clinical application in China, but not in the other
countries.

1.4. Molecular mechanisms of E1b55K-deleted Ad selectivity in cancer cells
Even though E1b55K-deleted oncolytic Ads have been used in several clinical
trials and is marketed in China, the mechanism(s) enabling this oncolytic
selectivity, remains controversial. The following sections summarize three
proposed mechanisms.

1.4.1. Cancer selectivity of E1b55K-deleted Ads based on p53 deficiency
The original mechanism proposed that E1b55K-deleted oncolytic Ad could only
replicate in p53-deficient tumor cells, but not in normal cells with functional p53
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(Fig. 1.2) (16, 17, 36). After virus infection, Ad E1A is expressed immediately to
regulate expression of viral genes and promote transduced cell entry into an
S-like cell cycle phase (37). In response to Ad infection, host cells have developed
a crucial strategy to block the virus spread by activation of p53-mediated
apoptosis and cell-cycle arrest after Ad infection and E1A expression (7, 38, 39).
Ad E1A triggers the accumulation of p53 protein either by activating p53
transcription, (40) or stabilizing p53 via inducing expression of p14ARF tumor
suppressor (referred to as p19ARF in murine cells) which binds to MDM2 protein
and subsequently blocks MDM2-induced p53 degradation and transactivational
silencing (41-43). Consequently, high levels of p53 in infected cells lead to either
cell-cycle arrest or apoptosis to block viral replication and spread.

In response to this, Ad has developed its ways to overcome p53-mediated
apoptosis and cell-cycle arrest triggered by Ad infection. It was reported that Ad
E1B55K protects the infected cells from the E1A-induced p53 effects through at
least three distinct mechanisms. First, E1B55K binds to the amino terminus of p53,
and thus represses p53 transactivation (44, 45). Second, E1B55K cooperates
with Ad E4orf6 to proteolytically degrade p53 (46-48). Third, E1B55K alone can
function as an E3 SUMO1-p53 ligase eventually also leading to p53
polyubiquitinylation and proteasomal degradation (49). Therefore in normal cells,
E1B55K counteracts the p53-dependent apoptosis induction by E1A and prevents
premature cell death, resulting in efficient viral replication (44, 45). Without
E1B55K protein, E1b55K-deleted Ads were considered to not be able to
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counteract E1A-induced p53 accumulation and thus fail to replicate in normal cells
with functional p53 protein. Deficiency of p53 occurs frequently in many types of
human cancers due to p53 gene deletion or mutation (50, 51). Since cancer cells
typically lack functional p53 protein or its pathways, the E1B55K function of
inhibiting p53 is not as important as it is in normal cells and thus it was proposed
that dl1520 could selectively replicate in cancer cells with dysfunctional p53
pathways (16, 17).

While some reports have supported the hypothesis that E1b55K-deleted Ads
selectively kill cancer cells with p53 deficiency, the original mechanism has been
challenged by several studies. Studies in our laboratory and others' have shown
E1b55K-deleted Ads are able to replicate in and kill cancer cells with wild-type
p53 as efficiently as in cancer cells with p53 deficiency (52-56). To resolve this
paradox, it was proposed that either p53 deficiency or p14ARF deficiency might
determine the cancer selectivity of E1b55K-deleted Ads (57, 58). In cancer cells
with wild-type p53, loss of the functional p14ARF would neutralize MDM2-mediated
p53 degradation and was considered to prevent p53 from its normal functions.
Thus p14ARF deficiency in cancer cells was indicated as the alternative molecular
mechanism to allow dl1520 replication in these cancer cells with wild-type p53.
However, experimental data contradicted this mechanism by showing that in
several cancer cell lines the replication of dl1520 is not controlled by the p53 or
p14ARF status (59).
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Also, it has been reported that in some cell lines, p53 can promote the viral lytic
cycle and may be required for productive virus replication and late viral gene
expression by cooperating with E1A to enhance transcription at the major late
gene promoter of the virus genome (60, 61). Further studies also revealed that
accumulation of p53 induced by E1b55K-deleted or E1b55K-mutated Ads can
neither efficiently induce apoptosis nor activate the transcription of downstream
p53-responsive genes in Ad-infected primary cells (62, 63). Moreover, in cells
which are infected with E1b55K-deleted Ads, E1b19K, as a homologue of BCL-2
family members, can also function as an inhibitor to adenovirus E1A
protein-induced apoptosis (38). Even if E1A-induced apoptosis occurs in
Ad-infected cancer cells, it does not prevent the replication of E1b-deleted
oncolytic Ads in the majority of cells (38). Thereby, blocking p53 activity may not
be the major requirement for viral replication, and p53 deficiency in cancer cells
seems unlikely to be the determinant of oncolytic selectivity of E1b55K-deleted
Ads.

So far none of the comprehensive research has been reported to sort out the
controversy existing between this mechanism model and currently available
literature. The lack of new experimental data to support the original hypothesis
hence raises the concern that the mechanism of cancer selectivity of
E1b55K-deleted oncolytic Ads has to be further addressed.
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that
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E1b55K-deleted Ads depends on p53 deficiency in cancer cells. E1B55K is
reported to inhibit p53 function, which prevents cellular p53-dependent apoptosis
induced by E1A, and thus allows virus to replicate. In normal cells with p53
expression, E1b55K-deleted oncolytic Ads do not contain E1B55K to counteract
E1A-induced p53 accumulation. The p53-mediated cell apoptosis therefore
prohibits E1b55K-deleted oncolytic Ads to replicate in those cells. However, in
p53-deficient cancer cells, lack of p53 expression allows oncolytic Ads to replicate
in the cells without undergoing E1A-induced apoptosis.
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1.4.2. Cancer selectivity of E1b55K-deleted Ads based on late viral mRNA
export
The mechanism that permissive cancer cells provide the late viral RNA export
functions for E1b55K-deleted Ads to carry out sufficient oncolytic replication was
proposed by O'Shea et al. (2004) (63) (Fig, 1.3). During the virus replication
process, the levels of late viral mRNAs raise in cytoplasm for translation whereas
the accumulation of cellular mRNAs in cytoplasm is blocked (7). E1B55K
functions in a complex with the viral E4orf6 protein to direct the switch from host to
viral protein synthesis by promoting the preferential nuclear export and translation
of the late viral mRNAs to cytoplasm (63-68). Several lines of evidence support
the hypothesis that the E1B55K/E4orf6 complex is directly involved in the
selective nuclear export of late viral mRNAs through active nucleocytoplasmic
shuttling via the exportin CRM1 (7, 64, 69) or through its E3 ubiquitin-protein
ligase activity (68, 70, 71). However, the molecular mechanism(s) of either
selective nucleocytoplasmic transport mediated by E1B55K/E4orf6 complex or
the assembly and activity of the E3 ubiquitin-protein ligase associated with
E1B55K/E4orf6

complex

has

not

been

fully

understood

(70).

Since

E1b55K-deleted oncolytic Ads lack E1B55K to mediate late viral mRNA export
from nucleus in primary cells, the viruses fail to efficiently replicate in those normal
cells (63). Permissive cancer cells, however, have a propensity to support the
nuclear export of viral late mRNAs in the absence of E1B55K while normal cells
do not, allowing oncolytic replication of E1b55K-deleted oncolytic Ads to occur.
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O'Shea et al. (2005) further reported that either restoring viral L4 100K protein
expression

or

inducing

heat

shock

responses

can

partially

rescue

E1b55K-deleted Ad replication in refractory cancer cells (72). In contrast to
permissive cancer cell lines, for E1b55K-deleted Ad replication, refractory cancer
cell lines fail to offer preferential nuclear export and translation of viral late mRNAs
including Ad L4 100K mRNA in the absence of E1B55K (72). Ad L4 100K is known
to be involved in host protein shutoff and promote preferential nuclear export and
translation of viral late mRNAs (73-75). As a consequence of the absence of
E1B55K, lack of L4 100K expression in refractory cancer cells leads to the poor
oncolytic Ad replication and ectopic expression of L4 100K in refractory cancer
cells enhanced the expression of late viral proteins. In the same report the authors
also implied that heat shock proteins overexpressed in various human cancers
may be the important molecular mechanism for cancer cells to support the
differential transport of late viral mRNA export between normal and cancer cells.
The cellular responses to heat shock resemble the late stages of adenovirus
infection with the inhibited translation of cellular mRNAs and preferential
translation of heat shock mRNAs. Also it has been shown that the 5'UTR of
mammalian heat shock protein (Hsp) 70 and late adenoviral mRNAs share
structural homology, which may contribute to both selective translation and
nuclear export through a common mechanism (76). Thus induction of heat shock
responses by physical or pharmacological means could selectively rescue the
export of late viral mRNAs in refractory cancer cells, rendering them once again
permissive to E1b55K-deleted Ad replication.
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However, although expression of L4 100K and inducing heat shock responses
may participate in determining the cancer selectivity of E1b55K-deleted Ads on
late viral mRNA export, limited evidence has also shown neither expressing L4
100K

nor

inducing

heat

shock

responses

could

completely

restore

E1b55K-deleted Ad replication to the level of wild-type Ad in a majority of cancer
cell lines. Since ectopic expression of L4 100K and inducing heat shock
responses cannot recover wild-type replication capacity in the absence of
E1B55K, the importance of E1B55K for selective oncolytic Ad replication cannot
be ignored. The exact mechanics of the interaction of E1B55K, L4 100K, and heat
shock responses to regulate mammalian and late viral mRNA export which leads
to cancer selectivity of E1b55K-deleted Ads still required for further studies.
Additionally, Gonzalez et al. (2006) indicated that it appears overly simplistic to
generalize that the cancer selectivity of E1b55K-deleted Ads relies on the
efficiency of viral late mRNA export (77). E1B55K has many more functions than
regulating the differential export of mRNAs, that are important for Ad replication
and therefore the outcome of a complex interaction between E1B55K and multiple
cellular components should be considered holistically in determining the cancer
selectivity mechanism.
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Normal cells
C

N
E1b55K-deleted
oncolytc Ads

Cancer cells
C

N

late viral mRNA

E1b55K-deleted
oncolytic Ad
replication

E1b55K-deleted
oncolytc Ads

Figure 1.3. Proposed mechanism that late viral mRNA export determines
oncolytic selectivity. "N" stands for nucleus and "C" stands for cytoplasm.
E1B55K/E4orf6 complex mediates the preferential export of late viral mRNAs
from cell nucleus (N) to cytoplasm (C) to carry out the translation. In normal cells,
a defect in late viral mRNA export of E1b55K-deleted Ads leads to the failure of
sufficient virus production. Cancer cells with properties to rescue this export and
expression of late viral mRNA to allow the oncolytic replication of E1b55K-deleted
Ads.
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1.4.3. Cancer selectivity of E1b55K-deleted Ads based on cyclin E or cell
cycle deregulation
Studies conducted by Goodrum and Ornelles (1999) showed that the E1B55K
function in late viral mRNA export may not correlate with the restricted replication
of E1b55K-deleted Ads in cells under G0/G1 phase (67). Unlike wild-type Ad which
is able to efficiently produce viral progeny regardless the cell-cycle stages, the
replication of E1b55K-deleted Ads is restricted in HeLa cells under G0/G1 phase
but less restricted in cells under S phase. Yet the total amount of cytoplasmic late
viral mRNA was found to be greater in cells infected during G1 phase than that in
cells infected during S phase with either the wild-type or E1b55K-deleted Ads. A
study further suggested that the E1B55K protein has a property to enable the
virus to overcome the growth restrictions to its replication imposed by the
cell-cycle stage (78).

Based on our study with large-scale gene arrays, we found that viral E1b products
affected the expression of numerous genes involved in cell cycle regulation,
transcription, apoptosis, protein metabolism, stress responses and angiogenesis
(79). Most importantly, the levels of some key regulators of cell cycle progression,
including cyclin E and CDC25A, were significantly increased by E1B.

Cyclin E is well-characterized as a critical cell cycle protein to promote G1/S
phase transition (80, 81) in either cyclin-dependent kinase 2 (CDK2)-dependent
(82) or CDK2-independent manner (83, 84). Expression of cyclin E is strictly
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controlled in normal cells while the deregulation of cyclin E is highly related to
tumorigenesis (85-88). Constitutive overexpression of cyclin E can induce
chromosome instability and impair normal cell cycle progression (89, 90). Cyclin E
gene amplification (91), overexpression of cyclin E mRNA or protein levels (87,
92), decrease of cyclin E turnover (93), together with the presence of more active
forms of cyclin E (94-96) have been reported in many types of cancers, such as
breast, gastrointestinal, lung and skin cancers.

We have reported that E1B55K has a novel function to induce cyclin E expression
which is critical for virus replication (56, 79). The replication of E1b55K-deleted
oncolytic Ads is restricted in normal cells due to the failure to induce cyclin E.
Cancer cells, with the cyclin E deregulation, may provide the E1B55K-like factors
to support cyclin E induction by E1b55K-deleted Ads, leading to sufficient
oncolytic replication. We thus proposed that cyclin E deregulation in cancer cells
is a molecular basis of oncolytic selectivity of E1b55K-deleted Ads (Fig. 1.4.).
Permissive cancer cells may provide E1B55K-like factors to relax cyclin E
regulation and allow E1b55K-deleted Ads to induce cyclin E expression similarly
to wild-type Ad in cancer cells, but not normal cells, leading to preferential
oncolytic replication. Ad-induced cyclin E subsequently activates CDK2 which
inhibits the transcriptional suppressor pRb to generate a cellular environment for
viral productive replication.
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E1B55K-like
cancer
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Adenovirus
replication
Ad E1B55K

cyclin E

Figure 1.4. Proposed mechanism that cyclin E deregulation in cancer cells
is the molecular basis of oncolytic selectivity. In Ad-infected normal cells, Ad
E1B55K functions to enhance cyclin E expression for virus replication. Without
E1b55K to induce cyclin E, E1b55K-deleted oncolytic Ads cannot replicate in
normal cells. Permissive cancer cells provide E1B55K-like factors to relax cyclin E
regulation and allow E1b55K-deleted Ads to induce cyclin E expression; leading
to preferential oncolytic replication.
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1.5. Scope of the dissertation
Ad dl1520 was originally created in United States, but the development for clinical
applications was aborted. However, this vector with a slight modification became
the first approved oncolyitc virus product (H101) on the China market and now
achieves some measure of success in cancer treatment (18). There is an urgent
need for us to improve current strategies to design viral vectors, and further
improve the insights into the field of oncolytic virotherapy. The work contained
within this dissertation has been proposed based on the hypothesis that cyclin E
deregulation in cancer cells is the molecular basis of oncolytic selectivity of
E1b55K-deleted Ads. We advanced the previous findings to further develop the
mechanism model to demonstrate the role of cyclin E in the selective replication of
E1b55K-deleted oncolytic Ads. The virtual application was then derived from the
knowledge of this mechanism model. Our laboratory then constructed a novel
tumor-specific oncolytic Ad-cycE with cyclin E promoter to drive E1A expression.
The oncolytic efficacy of this novel oncolytic Ad vector has been evaluated in vitro
and in vivo. Additional work has been completed exploring the impact of a
combination treatment with Ad-cycE and rapamycin which induces rapamycin in
lung cancer. Ultimately, by uncovering the selective replication mechanism of
oncolytic Ad and its further application, we hope to overcome the current
limitations; leading to advancement for the field of oncolytic virotherapy.
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CHAPTER II
MOLECULAR BASIS FOR VIRAL SELECTIVE REPLICATION IN CANCER
CELLS: ACTIVATION OF CDK2 BY ADENOVIRUS-INDUCED CYCLIN E

2.1. Introduction
Human adenoviruses (Ads) are double-stranded linear DNA viruses that are able
to infect and replicate in a wide variety of cell types in vitro and in vivo, including
post-mitotic cells. After infection, viral early proteins interact with cellular factors to
create favorable environments for viral replication (37). The Ad E1 region contains
two sets of genes, E1a and E1b, that are dedicated to cell cycle control, apoptotic
inhibition, and cellular and viral gene regulation (97). Ads with E1 modifications
that preferentially replicate in cancer cells have been used for cancer gene
therapy (15-17).

The viral E1a gene is expressed immediately after infection. The primary role of
E1a gene products is to regulate expression of multiple cellular and viral genes
(37). Instead of directly binding to specific DNA sequences in transcriptional
regulation elements, E1A proteins interact with several key regulators of cell
proliferation (98, 99). The well-known cellular factors to which E1A proteins bind
are products of the retinoblastoma (Rb) gene and its structurally related genes,
p107 and p130 (100, 101). By sequestering the retinoblastoma protein (pRb), E1A
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activates transcriptional regulator E2F proteins. Studies have suggested that the
pRb/E2F complex actively represses transcription from target genes and
mediates G1 arrest triggered by p19 (ARF), p53, p16INK4a, TGF beta, or cell
contact (102-104). Recently Pelka et al. (2011) indicated that E1A can directly
bind to E2F/DP complexes by interacting with DP-1, resulting in the activation of
E2F-responsive gene expression independently of binding to pRb (105). Several
groups have shown that expression of E1a gene triggers the accumulation of p53
protein and p53-dependent apoptosis (40, 106) either by activating p53
transcription or preventing p53 from being degraded by the proteasome (40, 41,
43, 106).

Ad E1B55K has been shown in some studies to counteract the E1A-induced
stabilization of p53 (106, 107). E1B55K protein may inhibit the functions of p53
through at least three distinct mechanisms. E1B55K reportedly binds the amino
terminus of p53 (44), and this binding may repress p53 transcriptional activation,
as suggested in transcription assays (45) and transient transfection studies (108).
E1B55K may also interfere with p53 function by cooperating with viral E4orf6
protein to cause proteolytic degradation of p53 protein (46-48). A recent study has
shown that E1B55K alone functions as an E3 SUMO1-p53 ligase that interacts
with promyelocytic leukemia nuclear bodies to inactivate p53 and stimulate its
nuclear export (49). Thereby, E1B55K blocks the expression of p53-regulated
genes and, consequently, counteracts the p53-dependent apoptosis induced by
E1A; allowing efficient viral replication (44, 45).
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Ad dl1520 (ONYX-015) contains an 827-bp deletion and a point mutation
generating a premature stop codon in the E1B55K coding sequence, preventing
expression from the gene (15). It was originally proposed that the E1b55K-deleted
Ads could replicate only in p53-deficient tumor cells, as the E1B55K-mediated
degradation of p53 protein was not required in those cancer cells (16, 109).
E1b55K-deleted oncolytic Ads have been tested in human clinical trials and are
being marketed for cancer treatment in China after approved by China's State
Food and Drug Administration (SFDA) (18). However, the original hypothesis was
challenged by several studies showing that E1b55K-deleted Ads are able to
replicate in cells regardless of their p53 status (52-55). Further studies have
shown that the accumulation of p53 protein, after infection with Ads carrying
mutated E1b55K genes that are unable to repress p53, can neither efficiently
induce apoptosis nor transcriptionally activate expression of p53-responsive
genes in Ad-infected cells (62, 63). Thus, these results suggest that blocking of
p53 activity by E1B55K protein is unlikely to be the major requirement for viral
replication. The mechanism(s) of E1b55K-deleted viral replication in cancer cells
is still not established, even though the vectors have already been applied in the
clinic for human cancer treatment (18).

Previously, we have shown that Ad E1B55K is involved in the induction of cell
cycle-related genes, including cyclin E and CDC25A (79). Ad E1B55K mediates
the large form of cyclin E protein (cyclin EL) induction in Ad-infected cells (56).
Cyclin E and the large form cyclin EL are generated from the alternative splicing.
The translation of cyclin EL is initiated at an ATG codon located in exon 2 and
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cyclin E is from the ATG codon in exon 3 (80). The E1B55K function is required for
cyclin EL induction in normal cells, but is not required in cancer cells with
deregulated cyclin E. Failing to efficiently induce cyclin EL expression in the
normal cells, replication of E1b55K-deleted oncolytic Ads is restricted. However,
E1b55K-deleted oncolytic Ads can efficiently induce cyclin EL in cancer cells and
carry out sufficient oncolytic replication. We proposed that cyclin E deregulation in
cancer cells may be an important molecular basis for the selective oncolytic
replication of E1b55K-deleted Ads (56).

Cyclin E regulates cell cycle progression, DNA replication (110, 111), and
centrosome duplication (112, 113). Expression of cyclin E is strictly controlled in
normal cells. The level of cyclin E rises at late G1 phase, peaks at the G1/S phase
to promote the S-phase entry, and decreases thereafter (80, 81). Deregulation of
cyclin E is frequently detected in many types of cancers, as cyclin E gene
amplification (91), overexpression of cyclin E mRNA or protein levels (87, 92),
decrease of cyclin E turnover (93), and the presence of more active forms of
cyclin E (94-96). Constitutive overexpression of cyclin E was shown to induce
chromosome instability and impair normal cell cycle progression (89, 90). The
hypothesis that abnormal cyclin E expression can trigger tumors has also been
supported by transgenic animal studies (86, 114, 115).

One function of cyclin E is to bind and activate cyclin-dependent kinase 2 (CDK2)
(82). The cyclin E/CDK2 complex then phosphorylates substrates such as pRb
and leads to transcriptional activation of downstream genes. Studies also indicate
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that cyclin E has CDK2-independent functions (83, 84). In vivo animal studies
indicate variance between the phenotypes of cyclin E null (cyclin E1 -/- E2-/-) mice
and CDK2 null (CDK2-/-) mice. Mice lacking CDK2 are viable, with normal
development except defective germ cell development (116, 117); yet knockout of
cyclin E1 and E2 genes in mice causes embryonic lethality owing to the deficiency
in endoreplication of trophoblast giant cells and megakaryocytes (118).
Matsumoto et al. (2004) identified a centrosomal localization signal (CLS) domain
in cyclin E (119). This CLS domain allows cyclin E to target the centrosome and
promote S phase entry in a CDK2-independent manner. Additionally, Geng et al.
(2007) showed that a cyclin E kinase-deficient mutant (KD-E) is able to partially
restore minichromosome maintenance protein (MCM) loading and S phase entry
in cyclin E null cells (83). Thus, cyclin E has CDK2-dependent and independent
functions in S phase entry and DNA replication. An important question is whether
Ad-induced cyclin E may activate CDK2 and whether the cyclin E-CDK2
interaction may play a crucial role in Ad replication. This question is especially
important in the development of oncolytic virotherapy strategies.

We report here that Ad-induced cyclin E binds with and activates CDK2 that
targets transcription repressor pRb, which in turn can regulate expression of
cellular and viral genes. The results suggest that the interaction between the
Ad-induced cyclin E and CDK2 is to generate a suitable environment for Ad
productive replication.
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2.2. Materials and Methods
Cell lines and culture conditions. HEK 293 (ATCC no. CRL-1573), human lung
fibroblast WI-38 (ATCC no. CCL-75), and human lung cancer A549 (ATCC no.
CCL-185) cell lines were purchased from the American Type Culture Collection
(Rockville, MD). WI-38 cells were cultured in minimal essential medium (MEM)
Alpha GlutaMAX with 0.1 mM non-essential amino acids and 1.0 mM sodium
pyruvate. HEK 293 and A549 cells were cultured in minimal essential medium
Alpha. All media were supplemented with 10% fetal bovine serum (FBS) and
penicillin/streptomycin (100 U/ml). Cells were cultured in a 5% CO2 incubator at
37°C. All cell culture reagents were obtained from Gibco BRL (Bethesda, MD).

Adenoviral vectors. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1
deletion carrying a green fluorescent protein (GFP), was used as a
replication-defective control. Adhz63, an oncolytic Ad vector with the deletion of
E1b55K region, was constructed by our laboratory (38).

Viral infection and titration. Cells were seeded into 6-well plates at a density of
2.5 x 105 (cells/well) and cultured under the indicated conditions. Subsequently,
cells were mock-infected or infected with AdGFP, Adwt, or Adhz63 at a multiplicity
of infection (MOI) of 5. Cytopathic effect (CPE) was observed at designed time
points and photographed with an inverted microscope (Olympus CKX41). Total
infected cells and culture supernatants were collected at 48 hr postinfection (p.i.)

25

and lysed to release virus particles with three cycles of freezing and thawing. The
viral titers were determined by the infective unit method as described previously
(120, 121). Briefly, HEK 293 cells were seeded in 96-well plates at a density of 103
(cells/well) and then infected with 5-fold serially diluted viruses. CPE was
recorded and scored after incubation for 7 days. The reduction percentage in virus
titer is calculated by the formula, reduction % = [(titer of control group – titer of
experimental group) / titer of control group] x 100%.

Viral DNA synthesis assay. After viral infection, cells were collected at different
time points. The viral DNA synthesis was determined with Southern blot; 1 µg of
isolated genomic DNA was digested with the restriction enzyme PstI and analyzed
with 1% agarose gel, which was subsequently transblotted to a Hybond-N+
membrane (YA3609; Amersham Pharmacia Biotech, Arlington Heights, IL). The
probe was prepared by digesting 0.5 µg pBHGE3 (122) with PstI and labeled by
following the protocol of Amersham AlkPhos Direct Labeling and Detection
Systems (RPN 3690; GE Healthcare, Piscataway, NJ). The blot was
prehybridized for 3 hrs at 63°C. The hybridization and stringency washes were
performed at 55°C and followed by the chemiluminescent detection according to
the manufacturer’s protocol.

Western blot analysis. Infected cells were harvested at indicated time points and
lysed with CDK2 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl 2,
0.5% Nonidet P-40, 0.1% Brij 35, 5 mM sodium glycerophosphate, 1 mM sodium
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vanadate, 1 mM dithiothreitol). The Western blot analyses were performed as
described previously (123). Briefly, 80 µg of cell lysates were electrophoresed
through 12% SDS-polyacrylamide gels and transferred onto an Immobilon-P
Membrane (Millipore, Billerica, MA). The primary antibodies used in this study
were rabbit anti-cyclin E (M-20), CDK4 (C-22), mouse anti-cyclin D1 (DCS-6),
PCNA (PC10), p21 (F-5), pRb (IF8) (Santa Cruz Biotechnology, Santa Cruz, CA),
mouse anti-CDK2, p27 (BD Biosciences, San Jose, CA), pCDK2 T160 (Cell
signaling, Danvers, MA), rabbit anti-phosphorylated pRb (phospho-pRb) S612,
and actin (Sigma, St. Louis, MO), anti-phospho-pRb S795 (New England Biolabs,
Beverly, MA), and anti-phospho-pRb T821 (Invitrogen, Carlsbad, CA). Actin was
used as an internal control. The membranes were then incubated with anti-mouse
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection
was performed with ECL reagents according to the supplier’s recommendations
(GE Healthcare). The scanned band intensity was quantitated by Gel-pro
Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) according to the
manufacturer’s tutorial. Densitometric value for each band was expressed as
integrated optical density (I.O.D.) and the results were normalized with actin. The
final values represent the means of relative percentage change, from at least
three independent experiments, compared with the mock group ± S.D.. Statistical
difference was assessed with Student's t-test. A p-value of <0.05 was considered
significant.
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Immunoprecipitation. A549 cells were seeded in 150 mm dishes at a cell density
of 5 x106 (cells/dish) and then mock-infected or infected with AdGFP, Adwt, or
Adhz63 at an MOI of 5. At 48 hr p.i., cells were collected and lysed with CDK2
lysis buffer according to the method described in previous publications (56, 124).
Cell lysates (500 µg) were immunoprecipitated with cyclin E (HE111), the mouse
monoclonal antibody (Santa Cruz), or anti-CDK2 antibody (BD Transduction
Laboratories) at 4°C for 4 hr, followed by adding protein A Sepharose CL-4B
(82506; Sigma) and incubating overnight. Immunocomplexes were analyzed by
Western blot with anti-cyclin E and CDK2 antibodies.

Small interfering RNA (siRNA) transfection. The siRNA oligonucleotides were
synthesized by Eurogentec (Fremont, CA). Three different siRNA duplexes were
designed to target CDK2 on nucleotides 399 to 419 (#1), 619 to 639 (#2), and 691
to 711 (#3) according to Genbank accession NM001798.2 (National Center for
Biotechnology Information GenBank). A negative control siRNA duplex containing
two strands of 19 complementary RNA bases with 3’dTdT overhangs was
obtained from Eurogentec (SR-CL000-005). Cells were seeded into a 6-well plate
at a density of 105 (cells/well) and then transfected with 200 nM CDK2 siRNA
duplexes or a non-specific control siRNA duplex with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Cells were
harvested at 48 hr after transfection. Eighty µg of cell lysates were analyzed by
Western blot with CDK2, pCDK2 T160, pRb, phosphorylated pRb (p-pRb), cyclin
E, capsid proteins, and actin antibodies.
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2.3. Results
Cyclin E/CDK2 complex formed in cells infected with adenoviruses. We have
previously established the link between cyclin E and replication of adenoviruses
(56, 79). The data shown in Figure 2.1 recapitulate that Ad E1B55K participates in
the induction of the large form of cyclin E protein (cyclin EL), which contributes to
the efficient viral replication. Cyclin E and cyclin EL are generated from alternative
splicing with different start ATG codons in exons 2 and 3 (80). The N terminus of
virus-induced cyclin EL is 15 amino acids longer than that of cyclin E protein.
Cyclin E protein is constitutively expressed in A549 human lung cancer cells (56).
Wild-type Ad5 (Adwt), with the intact E1b55K region, induced significant cyclin EL
expression in both of WI-38 human lung fibroblast cells and A549 human lung
cancer cells (Fig. 2.1A, lanes 2 and 5), and caused efficient cytopathic effect (CPE)
(Fig. 2.1B, panels b and e). Ad vector Adhz63 with E1b55K-deletion (38) also
induced significant cyclin EL in A549 cells (Fig. 2.1A, lane 6) and caused efficient
CPE of the cells (Fig. 2.1B, panel c). However, the vector failed to induce cyclin
EL overexpression in WI-38 cells (Fig. 2.1A, lane 3) and their CPE (Fig. 2.1B,
panel f). To compare the replication of Adwt and Adhz63 in A549 and WI-38 cells,
the titers of these two viruses were determined. The Adhz63 replication was
strongly repressed in WI-38 cells, showing only 10% of relative replication in
comparison with Adwt (Fig. 2.1C). When we compared Adhz63 replication with
that of Adwt in A549 cells, consistent with the CPE results, 80% of relative
replication of Adhz63 was observed. Thus, Adhz63 replication is more repressed
in WI-38 cells than in A549 cells. The result is consistent with our previous
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observation that cyclin EL induction in cancer cells is connected with the selective
replication of E1b55K-deleted Ads in cancer cells (56).
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Figure 2.1. Virus replication is correlated with cyclin E overexpression.
WI-38 or A549 cells were infected with AdGFP, Adwt or Adhz63 at an MOI of 5. (A)
Cells were collected at 48 hr and then analyzed by Western blot. Cell lysates were
immunoblotted for cyclin E and actin. Actin was used as a loading control. (B)
CPE was photographed at 72 hr post infection (p.i.). All microscopy was originally
at a magnification of x100. (C) Viral titers were determined at 72 hr p.i. with the
infection unit method. The value indicates the mean of three independent
experiments, shown as the mean change percentage relative to Adwt control
group ± S.D. * P<0.05 compared with the Adwt group, Student’s t-test.
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Cyclin E can promote the S phase entry and participate in DNA replication via
CDK2-dependent (82) and CDK2-independent pathways (119). To study whether
cyclin E function in Ad replication is CDK2 dependent or independent, we first
sought to investigate the physical contact between CDK2 and cyclin EL in cells
affected by Ads. Lung cancer A549 cells were mock-infected or infected with
AdGFP, Adwt, or Adhz63. To understand how E1b-deleted Ads selectively
replicate in cancer cells, we focused on A549 lung cancer cells in which both Adwt
and the E1b-deleted Adhz63 can efficiently induce cyclin EL and replicate. At
48 hr post-infection (p.i.), cells were collected and lysed. We first used anti-cyclin
E

antibody

to

immunoprecipitate

cyclin

E

protein

and

analyzed

the

immunocomplexes with Western blot. The data show that cyclin E protein
precipitated from cells mock-treated or treated with replication-defective AdGFP
(negative controls) did not exhibit significant association with CDK2 protein (Fig.
2.2A,

lanes

1

and

2).

However,

immunocomplexes

from

Adwt-

and

Adhz63-infected A549 cells contained both cyclin E and cyclin EL with an increase
of CDK2 binding (Fig. 2.2A, lanes 3 and 4). To verify this cyclin E/CDK2 bonding,
we also used anti-CDK2 antibody to pull down the protein complex and then
examined the level of cyclin E proteins in the cyclin E-CDK2 complex. The
immunoprecipitated CDK2 protein was increased in Adwt and Adhz63-infected
cells with a concomitant precipitation of cyclin EL (Fig. 2.2B, lanes 3 and 4),
especially

for

Adwt-infected

cells

(lane

3).

The

results

show

that

replication-competent Adwt and Adhz63 induce cyclin EL expression and increase
the formation of cyclin EL/CDK2 complex in A549 cancer cells, indicating that the
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cyclin EL induced in Ad-infected cells strongly associates with CDK2.
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Figure 2.2. Cyclin E/CDK2 complex induced by viral infection in A549 cells.
(A) A549 cell lysates were immunoprecipitated with anti-cyclin E antibody (1:50
dilution). Immunocomplexes were analyzed by Western blot with cyclin E and
CDK2 antibodies. (B) The cell lysates were immunoprecipitated with anti-CDK2
antibody and immunoblotted for CDK2, cyclin E and cyclin EL.
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Adenovirus-induced cyclin EL increases CDK2 phosphorylation. CDK2 is
activated by the phosphorylation at the T160 site and this phosphorylation
increases its electrophoretic mobility, resulting in faster-migrating bands (125). We
investigated whether cyclin EL induction and the increased interaction between
cyclin EL and CDK2 in A549 cells after Adwt and Adhz63 infection may promote
CDK2 phosphorylation at the specific T160 site. Analysis of the cell lysates with
Western blot demonstrated that the cyclin EL induction led to an increase of the
faster-migrating CDK2, consistent with phosphorylated-CDK2 protein (pCDK2)
T160 (the active form of CDK2), especially at 48 hr p.i. (Fig. 2.3A, lanes 7 and 8).
We verified the faster-migrating form of CDK2 with phospho-CDK2 (T160)
antibody (#2561, Cell signaling). Densitometric analysis of these bands
demonstrated that Adwt infection caused a 1.3 to 2.7-fold increase (P = 0.03) in
the level of pCDK2 T160 and Adhz63 infection caused a 1.5 to 1.9-fold increase
(P = 0.0026) compared with the mock-control group at 48 hr p.i. (Fig. 2.3B, lanes
3 and 4). The result in Figure 2.3B is consistent with that in Figure 2.3A (lanes 7
and 8).

In addition to cyclin E, cyclin D is also involved in the transition of the G1-S phase.
Thus, we also examined the level of cyclin D. Interestingly, the level of cyclin D
was decreased after viral infection. Densitometric analysis of the bands
demonstrated that Adwt and Adhz63 infection at 24 hr decreased cyclin D protein
to the levels of 11% (P = 0.0000025) and 71% (P = 0.001) of the mock infection,
respectively (Fig. 2.3C, lanes 3 and 4). The levels of cyclin D in cells infected with
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Adwt or Adhz63 were further decreased at 48 hr to 3% (P = 0.00000043) and 8%
(P = 0.00002), respectively (Fig. 2.3C, lanes 7 and 8). Meanwhile, the level of
CDK4 and the proliferating cell nuclear antigen (PCNA) did not significantly
change in any of the groups. CDK4 is regulated and activated by cyclin D to
process the G1-S transition (126, 127); PCNA, known to regulate DNA replication
and DNA repair, is associated with multiple cyclin/CDK complexes in the cell-cycle
progression (128, 129). The results show that Ads decreased cyclin D production
and did not affect the levels of CDK4. Thus, Ad infection specifically induced
cyclin EL that activated CDK2 via phosphorylation at its T160 site, suggesting a
critical role of cyclin EL and CDK2 in Ad replication.

37

38

Figure 2.3. Effects of viral replication on cellular proteins related to G1/S
phase. A549 cells were mock infected or infected with AdGFP, Adwt, or Adhz63 at
an MOI of 5. Cells were collected at 24 hr or 48 hr p.i. and then analyzed by
Western blot. Cell lysates were immunoblotted for (A) cyclin E and CDK2; (B)
pCDK2 T160; and (C) cyclin D, CDK4 and PCNA. Actin was used as a loading
control. The scanned band intensity was quantitated and the values represent the
means of the relative change percentages compared with the mock group ± S.D.
from three independent triplicate experiments. * P<0.05 compared with the
mock-control group, Student’s t-test.
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Adenoviruses

increase

pRb

phosphorylation.

Cyclin

E-activated

phosphorylated CDK2 (pCDK2) is known to control the G1-S transition by
phosphorylation of the downstream substrates. Considering that pRb is one of the
well-known targets for pCDK2, we examined whether the increase of activated
pCDK2 alters the phosphorylation of pRb at S612, which is a CDK2-preferred
phosphorylation residue (130, 131). We found that the level of phospho-pRb S612
was increased to 314% (P = 0.016) and 240% (P = 0.03) in cells infected with
Adwt

and

Adhz63,

respectively,

even

though

the

protein

level

of

unphosphorylated pRb is decreased slightly (Fig. 2.4A, lanes 3 and 4). We could
not detect any significant changes of p-pRb T821, another CDK2-preferred
phosphorylation residue (130, 132), and the CDK4-preferred p-pRb S795 (133)
(Fig. 2.4A). The results suggest the selection of the S612 site in pRb by
Ad-activated CDK2 for protein phosphorylation.

Adenoviruses repress CDK inhibitors. We also observed that the protein levels
of both p21 and p27 are decreased in A549 cells infected with Adwt and Adhz63,
especially for p21 (Fig 2.4B). p21 and p27 are the well-known CDK inhibitors,
which negatively regulate the activity of cyclin E/CDK2 complexes to prevent the
cell-cycle progression (134). Densitometric analysis of these bands demonstrated
that the level of p21 protein decreased to the levels of 8% (P = 0.0000002) and
44% (P = 0.00066) of the mock control in A549 cells after infection with Adwt and
Adhz63 at 24 hr, respectively (Fig. 2.4B, lanes 3 and 4). The p21 level was further
repressed in A549 cells at 48 hr after infection with Adwt (2%, P = 0.00000034)
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and Adhz63 (6%, P = 0.0000007) (Fig. 2.4B, lanes 7 and 8). Ad infection also
decreased p27 protein levels to 36% (Adwt, P = 0.0015) and 49% (Adhz63, P =
0.00043) at 24 hr; 16% (Adwt, P = 0.00012) and 37% (Adhz63, P = 0.0092) at 48
hr in A549 cells (Fig. 2.4B). The results suggested that Ads activate the CDK2 by
inducing cyclin EL and repressing p21 and p27.
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Figure 2.4. Effects of viral replication on pRb and CDK inhibitors. A549 cells
were mock-infected or infected with AdGFP, Adwt, or Adhz63 and collected at 24
hr or 48 hr p.i., followed by Western blot analysis. Cell lysates were
immunoblotted for (A) pRb, phospho-pRb (p-pRb) at S612, T821 and S795 or (B)
p21 and p27. Actin was used as a loading control. * P<0.05 compared with the
mock-control group, Student’s t-test.
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Interruption of cyclin EL and CDK2 interaction reduces adenoviral
replication. To further investigate the role of CDK2 in viral replication, we used
the CDK2 chemical inhibitor roscovitine (Ros; CYC202) to interrupt cyclin EL and
CDK2 interaction. Ros is a purine derivative that inhibits the activity of CDK2 by
binding to its active site (135). Ros reduces phosphorylation on CDK2 (136) and
blocks the androstenedione-induced increase of active phosphorylated CDK2
(137). If activation of CDK2 is required for viral replication, blocking CDK2 activity
should reduce it. Figure 2.5A, representing one of the four repeated experiments,
shows that with increased Ros, CPE caused by Adwt and Adhz63 infection was
partially inhibited. Figure 2.5B shows that treatment with 5 µM of Ros led to a 50%
reduction in Adwt titer (P = 0.0002) and 71% reduction in Adhz63 titer (P = 0.034)
when compared with the vehicle-control group treated with dimethyl sulfoxide
(DMSO, defined as 0 µM Ros). Treatment with 10 µM Ros led to more decreases
of viral titers: 81% reduction in Adwt (P = 0.00001) and 87% reduction in Adhz63
(P = 0.012). The repressed viral yields are consistent with the CPE phenomenon
in Figure 2.5A.
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Figure 2.5. Effects of roscovitine on CPE and viral production. (A) Cells were
treated with 0 µM (vehicle-control group treated with DMSO), 5 µM, or 10 µM
roscovitine, and mock-infected or infected with AdGFP, Adwt or Adhz63 at an MOI
of 5. All microscopy is originally at a magnification of x100 taken at 48 hr p.i. (B)
Viral titers were determined at 48 hr p.i. with the infection unit method. The values
represent the means ± S.D. of independent quadruplicate. * P<0.05 compared
with the 0 µM roscovitine, Student’s t-test.
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We then examined the levels of viral DNA and proteins produced in cells affected
by Ros treatment. The viral DNA synthesis was determined by Southern blot
probed with the Ad genome. The linear Adwt DNA is 36 Kb with total 28 PstI
restriction sites. The largest fragment is 4333 bp and the smallest fragment is only
12 bp. The sizes of the representative DNA fragments were marked on Figure 2.6.
The viral DNA synthesis of Adwt and Adhz63 at 24 hr p.i. was strongly inhibited in
the presence of 10 µM Ros (Fig. 2.6A, lanes 6 and 12). Consistently, the viral
capsid proteins were significantly inhibited in the presence of 10 µM Ros (Fig.
2.6B, lanes 4 and 6). Inhibition of CDK2 activity with Ros reduced the
phosphorylation of pRb at the S612 site in AdGFP, Adwt and Adhz63-treated cells
(Fig. 2.6C). Interestingly, Ros treatment markedly repressed the induction of
cyclin EL protein caused by Adwt and Adhz63 infection (Fig. 2.6C, lanes 4 and 6).
To sum up, these data show that inhibition of CDK2 with Ros repressed pRb
phosphorylation and inhibited viral replication.
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Figure. 2.6. Effects of Ros on viral DNA synthesis, viral capsid proteins,
virus-induced cyclin E and phospho-pRb S612. (A) A549 cells were collected
at 0 hr and 24 hr p.i. Viral DNA synthesis was determined by Southern blot. At 24
hr p.i., cells were harvested and cell lysates were immunoblotted for (B)
adenovirus type 5 capsid proteins, (C) cyclin EL, p-pRb S612, and actin. Actin
was used as a loading control. * P<0.05 compared with the 0 µM
roscovitine-treated group, Student’s t-test.
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siRNA inhibiting CDK2 represses adenoviral replication by preventing pRb
phosphorylation. Since the chemical inhibitor Ros may also influence other CDK
and kinases (138), we also applied RNA interference to specifically silence CDK2
expression. We tested three different pairs of siRNA duplexes targeting CDK2 on
the coding region and showed that all CDK2 siRNAs dramatically inhibited CDK2
expression without the detectable influence on the non-targeted CDK4 in A549
cells (Fig. 2.7A). To evaluate the effects of CDK2 on the cellular protein production
in response to viral infection, A549 cells were infected with Adwt or Adhz63 after
treatment with CDK2 siRNA duplex or a non-specific control siRNA for 48 hours.
Figure 2.7B, representing one of the three repeated experiments, shows that
blockage of CDK2 expression with siRNA partially inhibited Adwt and
Adhz63-induced CPE. Inhibition of CDK2 expression with siRNA resulted in the
decreases of Adwt titer from 1.4 X 109 (control siRNA) to 2.8 X 108 (specific siRNA)
and Adhz63 titer from 1.2 X 108 to 4.2 X 107 (Fig. 2.7C). The effect of CDK2
siRNA on viral replication is statistically significant; the titers decreased about 5
fold for Adwt (P = 0.0005) and 3 fold for Adhz63 (P = 0.03).

We also evaluated the effects of CDK2 on the cellular protein production in
response to viral infection. As we expected, the CDK2 siRNA specifically
repressed the production of CDK2 protein and decreased pCDK2 T160 in Adwt
and Adhz63-infected cells (Fig. 2.7D, lanes 2 and 4). Repression of CDK2 also
resulted in reduced CDK2-specific phosphorylation on pRb, but did not decrease
pRb protein levels. In addition, we observed that treatment with CDK2 siRNA
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repressed specifically Ad-induced cyclin EL, but not cyclin E (Fig. 2.7D, lanes 2
and 4). This agreed our findings with Ros (Fig. 2.6C) showing that specifically
inhibiting CDK2 with siRNA significantly repressed viral production, which
correlated with the decreased CDK2 activation and phosphorylation on pRb in
cancer cells.
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Figure 2.7. Effects of CDK2-specific siRNA on Ad replication in A549 human
lung cancer cells. (A) A549 cells were transfected with 200 nM siRNA duplexes
targeting different coding regions of CDK2. “Mix” represents the mixture of three
pairs of siRNA duplexes (#1, #2 and #3). Cells were harvested at 48 hr after
transfection. Cell lysates were immunoblotted for CDK2, CDK4, and actin. (B) At
48 hr after transfection with CDK2 siRNA duplex or a duplex of non-specific
control siRNA, cells were infected with Adwt or Adhz63 at an MOI of 5. CPE was
photographed at 48 hr p.i. All microscopy is originally at a magnification of x100.
(C) The viral titers were determined at 48 hr p.i. with the infection unit method.
The values are means ± S.D. of independent triplicate. * P<0.05 compared with
the control group, Student’s t-test. (D) The infected cells were harvested at 24 hr
after infection. Cell lysates were immunoblotted for CDK2, pCDK2 T160, pRb,
p-pRb S612, cyclin E, cyclin EL, and actin. Actin was used as a loading control.
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siRNA inhibiting CDK2 repressed wild-type adenovirus replication in normal
cells. Considering that the control of G1 exit is generally abnormal in cancer cells,
we verified the role of CDK2 in Ad replication in WI-38 human diploid cell line that
was derived from the normal embryonic lung tissue (139). As Adhz63 poorly
induces cyclin EL and replicates in WI-38 cells (Fig. 2.1), we therefore
investigated Adwt replication in WI-38 cells with the non-replication AdGFP as a
negative control. WI-38 cells were infected with AdGFP or Adwt after transfected
with CDK2 siRNA duplex or a non-specific control siRNA for 48 hr. Figure 2.8A,
representing one of the three repeated experiments at 72 hr p.i., shows that
blockage of CDK2 expression with siRNA partially inhibited Adwt-induced CPE as
we observed with Adwt-infected A549 cells. Inhibition of CDK2 expression with
the specific siRNA caused a significant decrease of Adwt titer from 2.2 X 108 to
1.8 X 107 (P = 0.03, Fig. 2.8B). In addition, CDK2 repression also dramatically
inhibited the viral DNA synthesis (Fig. 2.8C, lane 4) and capsid protein production
(Fig. 2.8D, lane 4).

The level of cellular proteins in response to viral infection altered by CDK2
inhibition was also examined in WI-38 cells. For cells treated with the non-specific
control siRNA, we were unable to detect pCDK2 T160 and cyclin E in WI-38 cells
treated with AdGFP (Fig. 2.8E); this is related to the strict control of cyclin E
expression in WI-38 cells. Adwt infection significantly increased CDK2, pCDK2
T160, and cyclin EL (Fig. 2.8E, comparing lanes 1 and 3). Inhibition of CDK2 by
the siRNA repressed the pCDK2 T160, phospho-pRb S612, and cyclin EL
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induced by Adwt infection (Fig. 2.8E, comparing lane 1 with 2 and lane 3 with 4).
Adwt infection and siRNA treatment did not show significant effects on pRb (Fig.
2.8E). Taken together, the results suggest that CDK2 activated by Ad-induced
cyclin EL plays a general and important role in the adenoviral replication in normal
cells.
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Figure 2.8. Effects of CDK2-specific siRNA on Ad replication in WI-38 human
lung fibroblast cells. WI-38 cells were transfected with CDK2 siRNA duplex or a
duplex of non-specific control siRNA. At 48 hr after transfection cells were infected
with AdGFP, Adwt, or Adhz63 at an MOI of 5. (A) CPE was photographed at 72 hr
p.i. All microscopy was originally at a magnification of x100. (B) The viral titers
were determined at 72 hr p.i. with the infection unit method. The values are
means ± S.D. of independent triplicate. * P<0.05 compared with the control group,
Student’s t-test. (C) Cells were collected at 48 hr p.i. and viral DNA synthesis was
determined by Southern blot. Cell lysates were immunoblotted (D) for adenovirus
type 5 capsid proteins and for (E) CDK2, pCDK2 T160, pRb, p-pRb S612 and
cyclin EL. Actin was used as a loading control.
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2.4. Discussion
By using multiple cell lines (A549, WI-38, HCT116, RKO, HepG2, Hep3B, Saos2,
HeLa, MDA-MB-231, and HT29), we previously have shown that induction of
cyclin EL is required for Ad replication and correlated with oncolytic selectivity of
E1B55K-deleted Ad (56, 79). In this report, we extended the study and focused on
cyclin E and CDK2 interaction in human lung cells that are natural host cells for
human adenoviruses; we demonstrated that CDK2 activation by cyclin EL is a
critical molecular step in Ad replication. Three lines of evidence support the
importance of activation of CDK2 by cyclin EL in Ad replication. First, Ad-induced
cyclin EL directly interacted with CDK2 and formed cyclin EL/CDK2 complex,
leading to specifically increased phosphorylation of CDK2 and pRb (CDK2 at
T160 and pRb at S612). Second, the CDK2 chemical inhibitor roscovitine
decreased viral replication. Finally, the siRNA specifically inhibiting CDK2
repressed the viral replication with the decrease in pRb phosphorylation. These
three lines of evidence support the hypothesis that Ad-induced cyclin EL activates
CDK2, which targets the transcriptional suppressor pRb, controlling cellular and
viral gene expression for productive viral replication (Fig. 2.9).
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Figure 2.9. Proposed mechanism of cyclin E function in Ad replication. In
Ad-infected cells, Ad E1B55K has a function to enhance cyclin E expression. This
E1B55K function is not required for virus replication in cancer cells, which may
provide E1B55K-like factors to relax cyclin E regulation and promote cell cycle
progression. Cyclin E binds to and activates CDK2. Subsequently, the active
pCDK2 phosphorylates the transcriptional repressor pRb, leading to the
expression of multiple genes, including cyclin E, to provide a suitable cellular
environment for viral replication.

58

Cyclin E and the large form cyclin EL are generated from alternative splicing. The
translation of cyclin EL is initiated at an ATG codon located in exon 2 and cyclin E
is from the ATG codon in exon 3 (80). It has been reported that cyclin EL is found
predominantly in breast tumor cells with the abundant lower-molecular-weight
(LMW) isoforms (140, 141). We previously constructed a plasmid, pTet-cycE,
containing cyclin E cDNA that produces these two forms of cyclin E proteins (56).
With this approach we clarified that the A549 cell line constitutively expresses the
regular cyclin E protein (cyclin E), and Ad infection mainly induces the expression
of large form cyclin E protein (cyclin EL) (56). It is still unclear why Ad infection
mainly induces cyclin EL. Considering that cyclin E has CDK2-dependent (82)
and independent functions that are related to participation in DNA replication
licensing (83) and oncogenic transformation (84), we studied whether Ad-induced
cyclin E may target and activate CDK2 in virus-infected cells for productive Ad
replication.

We first examined the physical interaction between virus-induced cyclin EL and
CDK2. The results indicated that Ad-induced cyclin EL preferentially associates
with CDK2 protein (Fig. 2.2). We cannot exclude that endogenous cyclin E in
A549 cells may also interact with CDK2; however, we observed that the increased
CDK2 in the cyclin E/CDK2 immunocomplexes was associated with cyclin EL
induction after infection with replication-competent Adwt and Adhz63. The results
suggested cyclin EL highly interacts with CDK2 in Ad-infected cancer cells. In
proliferating cells, the abundance of the cyclin E protein directly links to the
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formation of active cyclin E/CDK2 complex (80, 142). With an intact cyclin box and
the C-terminal 50 amino acids, the full-length cyclin EL is able to bind and activate
CDK2 as cyclin E (82, 84). Consistent with our finding, previous studies showed
that the addition of exogenous cyclin EL increases the formation of cyclin
EL/CDK2 complex correlating to the increased activity and phosphorylation of
CDK2 in human lung fibroblasts (80) and breast cancer cells (143). We reason
that Ad-induced cyclin EL may have a strong affinity to CDK2 in the cellular
environment affected by Ad infection.

We identified that Ad-induced cyclin EL correlates with the increase in
phosphorylation of CDK2 at T160 and pRb at S612 (Figs. 2.3B and 2.4A). Three
phosphorylation sites have been identified in CDK2 (125). T160 phosphorylation
is essential for CDK2 activity, while T14 and Y15 phosphorylation cause an
inhibitory effect. The retinoblastoma tumor suppressor pRb is inactivated by
CDK’s phosphorylation and enables E2F transcription factor to be released from
the pRb/E2F complex to carry out the downstream gene regulation (144, 145).
Phosphopeptide analysis of pRb showed that S612 is one of the CDK2-preferred
phosphorylation sites (130). We also examined the level of pRb with
phosphorylation of T821 (CDK2-preferred) and S795 (CDK4-preferred); we did
not detect any significant change at either of these two sites (Fig. 2.4A). Inhibition
of CDK2 expression with the CDK2 siRNA repressed phosphorylation on CDK2
and pRb (Fig. 2.7D) and decreased viral replication (Fig. 2.7C). These results
indicate that Ad-induced cyclin EL activates CDK2 by phosphorylating at T160,
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which then specifically introduces pRb phosphorylation at the S612 site.

The pRb phosphorylation by cyclin EL/CDK2 may lead to regulation of multiple
cellular and viral genes for productive Ad replication. Interestingly, Ad-induced
cyclin EL expression was also inhibited by a CDK2 chemical inhibitor and CDK2
siRNA (Figs. 2.6C, 2.7D and 2.8E). It seems that inhibition of CDK2 interferes in
the cyclin E induction via a loopback regulation (Fig. 2.9). Previous studies have
reported that cyclin E gene is the downstream target of E2F (146, 147). In our
previous work, we showed that the cyclin E promoter is more active in cancer
cells and the promoter activity is further enhanced after Ad infection (56). We
suggest that cyclin EL activates the cyclin EL-CDK2-pRb/E2F pathway and cyclin
EL itself is also one of the targets of the pathway.

We detected a notable decrease of CDK inhibitors p21 and p27 in the Ad-infected
cells. p21 and p27 inhibit the activity of cyclin/CDK complexes to prevent the
cell-cycle progression, and their protein stability is also regulated by cyclin/CDK
complexes (134, 148, 149). Phosphorylation of p27 by cyclin E/CDK2 causes p27
degradation (148, 150). Montagnoli et al. (1999) showed that cyclin
E/CDK2-dependent phosphorylation of p27 at threonine 187 facilitates the
formation of a trimeric complex with cyclin E/CDK2 and leads to p27 ubiquitination
(151). In agreement with our findings, recent studies also suggest that CDK may
promote p21 degradation (149, 152). Thus, the activated cyclin E and CDK2 may
decrease the CDK inhibitors p21 and p27 to benefit viral replication.
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In summary, our results showed that Ad-induced cyclin EL binds to and activates
CDK2 that subsequently phosphorylates the transcriptional suppressor pRb,
which can regulate expression of multiple cellular and viral genes, including cyclin
E (Fig. 2.9). Our previous studies have shown that Ad E1B55K has a function to
enhance cyclin E induction. In cancer cells, this E1B55K function is not critically
required for cyclin E induction and viral replication, likely because of deregulated
cyclin E expression or having E1B55K-like cancer cellular factors. This study
demonstrated that Ad-induced cyclin EL plays a critical role in Ad replication
through activation of CDK2 that generates a suitable environment for viral
replication. Our study reveals a new molecular basis for Ad replication in cancer
cells that will guard us to develop new oncolytic vectors and therapeutic
strategies.
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CHAPTER III
ONCOLYTIC ADENOVIRUS TARGETS CYCLIN E OVEREXPRESSION AND
INHIBITS TUMOR DEVELOPMENT IN VIVO

3.1. Introduction
Oncolytic virotherapy with self-replicating and cancer-selective viruses has
emerged as a new hope for cancer treatment. The therapeutic effects of oncolytic
viruses are initiated from small amount of viruses and spread to surrounding
tumor cells, and thus has been considered as an attractive drug platform (4, 153).
Gene-attenuated replication-competent adenovirus (Ad) ONYX-015/dl1520 has
been applied to several preclinical (16, 36, 154) and clinical studies in the United
States (17, 18). With the structure similar to dl1520 and slight modification, H101
has been commercially approved for cancer treatment in China.

Although dl1520 has achieved some measure of success in solid tumor treatment,
the native E1a promoter on dl1520 is constitutively active and thus leads to the
safety concerns that virus may replicate in normal cells to cause toxicity (155-157).
The major strategy to increase tumor specific replication of oncolytic Ads depends
on transcriptionally regulating the essential E1A expression by tumor-specific
promoters (6, 158). The proteins encoded by the E1a region are expressed
immediately after infection, and these gene products modulate the cell cycle,
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recruit cellular proteins, and produce viral proteins to process viral DNA replication
(37). By replacing native E1a promoter with cellular promoter preferentially active
in tumor rather than normal tissues, oncolytic Ads can carry out more selective
replication restricted in tumors. Some tumor-specific promoter based oncolytic
Ads such as human telomerase reverse transcriptase (hTERT)-promoter driven
OBP-301 (Telomelysin) (32) and prostate-specific antigen (PSA)-promoter driven
CV706 (29) have been evaluated in clinical trials. Nevertheless, most known
tumor-specific promoters are only active in a narrow range of tumors with relative
weak activity compared with the constitutive viral promoters which are
ubiquitously active (159-163). Also, our published microarray study indicates virus
infection causes strong repression of various cellular promoters (79). Lacking
consideration for the negative effects imposed by virus infection on those
promoters may narrow our insight and thus hinder the future vector design.

Cyclin E is known to regulate cell cycle progression (80), DNA replication (110,
111), and centrosome duplication (112, 113). Numerous types of cancers such as
lung cancer and breast cancer are highly associated with dysregulation of cyclin E
(87). Constitutive overexpression of cyclin E induces chromosome instability (89,
90), impairs normal cell cycle progression and triggers tumorigenesis in
transgenic animal models (86, 114, 115). Previously we have demonstrated that
cyclin E overexpression is a molecular basis of selective oncolytic replication of
E1b55K-deleted Ads in human cancer cells (56, 79). Ads induce cyclin E which
activates CDK2 that targets the transcriptional repressor pRb, turning on the
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downstream gene expression to adjust the cellular environment for productive
viral replication (164). We also reported that cyclin E promoter, highly active in
cancer cells, is further augmented during viral reproduction process (56, 165).
The unique properties of cyclin E promoter in virus replication indicate its potential
on the oncolytic vector design. Based on these findings, we generated a novel
E1b-deleted Ad-cycE in which the E1a gene is under the control of the human
cyclin E promoter. E1A expression driven by the cyclin E promoter in Ad-cycE can
be enhanced by dual pathways. Since the cyclin E promoter is already highly
active in many types of cancer cells, the initial E1A expression will be driven by
activation of cyclin E promoter by cancer cellular factors, leading to selective viral
replication. The activity of cyclin E promoter can also be further augmented by Ad
itself as we have shown that cyclin E expression is significantly upregulated in
cancer cells after Ad infection (Fig. 3.1).
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Figure 3.1. Proposed rationale of activating E1A transcription in Ad-cycE
vector. Ad-cycE is an E1b-deleted oncolytic Ad carrying a cyclin E promoter
(cycE-P) to drive an intact E1A expression cassette. With dual properties to target
the cyclin E overexpression in cancer cells and virus-induced environment, cyclin
E promoter may allow either the cellular factors from cancer cells or the viral
factors from viral reproduction process to activate virus E1A transcription in
Ad-cycE.
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Our results revealed that a novel therapy Ad-cycE targets cyclin E overexpression
in cancer cells, significantly represses tumor growth and prolonged survival of
nude mice bearing human lung cancer xenograft. The vector also shows selective
and efficient antitumor effects on cancer cell lines reported as non-permissive for
dl1520 replication. This study not only provided the attractive insight for the future
design of the oncolytic Ad vectors, but also unraveled the potent antitumor
efficacy by targeting cyclin E overexpression in cancer cells and viral reproduction
process.
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3.2. Materials and Methods
Cell lines and culture conditions. Human embryonic kidney HEK 293 (ATCC no.
CRL-1573), lung fibroblast WI-38 (ATCC no. CCL-75), lung cancer A549 (ATCC
no. CCL-185) and H1299 (ATCC no. CRL-5803), prostate cancer DU-145 (ATCC
no. HTB-81) and LNCaP (ATCC no. CRL-1740), osteosarcoma Saos2 (ATCC no.
HTB-85), and breast cancer MDA-MB-231 (ATCC no. HTB-26) cell lines were
purchased from the American Type Culture Collection (Rockville, MD). HEK 293,
A549 and MDA-MB-231 cells were cultured in DMEM. Saos 2 cells were cultured
in McCoy's 5A. LNCaP and H1299 cells were cultured in RPMI-1640 medium.
WI-38 cells were cultured in minimal essential medium (MEM) Alpha GlutaMAX
with 0.1 mM non-essential amino acids and 1.0 mM sodium pyruvate. All media
were

supplemented

with

10%

fetal

bovine

serum

(FBS)

and

penicillin/streptomycin (100 U/ml). Cells were cultured in a 5% CO2 incubator at
37°C. All cell culture reagents were obtained from Gibco BRL (Bethesda, MD) and
Corning Cellgro (Manassas, VA).

Adenoviral vectors. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1
deletion carrying a green fluorescent protein (GFP) constructed in our laboratory
(166), was used as a replication-defective control. Ad dl1520 is a E1b55K mutant
which contains an 827-bp deletion and a point mutation to generate a premature
stop codon in the E1B55K coding region (15). Adhz55 is a E1b-deleted oncolytic
vector carrying prostate-specific ARR2PB promoter (167) driving an intact E1A
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expression cassette constructed in our laboratory. Ad-cycE is a novel E1b-deleted
oncolytic vector carrying a human cyclin E promoter driving an intact E1A
expression cassette. To prepare Ad-cycE vector, 671 bp of human cyclin E
promoter (GenBank ID: X95406) (168, 169) was released by digesting
pGL-2-cycE promoter 10-4 plasmid (Addgene, Cambridge, MA) with SmaI and
the fragment was ligated into the shuttle plasmid pMEa301 which contains
promoterless E1a region and the deletion of E1b to generate pBZ400 plasmid.
The pBZ400 plasmid contains cyclin E promoter, together with entire E1a open
reading frame and E1b deletion. pBHGE3 plasmid (122) containing Ad genomic
DNA and pBZ400 plasmid were cotransfected into 293 cells. Ad-cycE was
rescued from cells after transfection and contains a human cyclin E promoter to
control E1a open reading frames (ORF) with the deletion of E1b region. All of the
vectors created and used in this study are based on the backbone of wild-type Ad
type 5.

Cytotoxicity assay. Cells were seeded into 24-well plates at a density of
2.5 x 104 (cells/well) and cultured under the indicated conditions. Cytotoxicity was
assessed with crystal violet staining (170). Cells were fixed with 3.7%
paraformaldehyde and stained with 1% crystal violet followed by washing with
water to remove excess dye. The dye was solubilized with 2% SDS and the
absorbance of the solubilized stain was measured at 590 nm using a Synergy HT
Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT). The OD values were
quantitated into the cell viability % by the formula, cell viability % = (OD value of
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experimental group / OD value of control group) x 100%. The mock-control group
was calculated as 100% of cell viability in the assay (171).

Western blot analysis. Infected cells were harvested at indicated time points and
lysed with CDK2 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl 2,
0.5% Nonidet P-40, 0.1% Brij 35, 5 mM sodium glycerophosphate, 1 mM sodium
vanadate, 1 mM dithiothreitol). The Western blot analyses were performed as
described previously (123). Briefly, 80 µg of cell lysates were electrophoresed
through 12% SDS-polyacrylamide gels and transferred onto an Immobilon-P
Membrane (Millipore, Billerica, MA). The primary antibodies used in this study
were rabbit anti-cyclin E (M-20), (Santa Cruz Biotechnology, Santa Cruz, CA),
mouse anti-adenovirus type 5 E1A (BD Pharmingen, San Jose, CA). Actin was
used as an internal control. The membranes were then incubated with anti-mouse
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection
was performed with ECL reagents according to the supplier’s recommendations
(GE Healthcare).

Viral titration. Total infected cells and culture supernatants were collected at the
indicated time points and lysed to release virus particles with three cycles of
freezing and thawing. The viral titers were determined by the infective unit method
as described previously (120, 121). Briefly, HEK 293 cells were seeded in 96-well
plates at a density of 103 (cells/well) and then infected with 10-fold serially diluted
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viruses. CPE was recorded and scored after incubation for 7 days.

Lung cancer xenograft study. Female athymic nude mice (NCr-nu/nu) were
obtained from National Cancer Institute (Bethesda, MD). 5 x 106 A549 human
lung cancer cells were subcutaneously injected into the flanks of mice (aged 6
weeks). Once palpable tumors were established (mean of tumor sizes
approximates to 20-25 mm3), the mice were randomized and received 5 × 108 IFU
of AdGFP or Ad-cycE in 50 μL PBS every 2 days for total 4 treatments. The
tumors were measured every 3 days until the tumor volume was greater than
1000 mm3. The tumor volume was determined by externally measuring in 2
dimensions with a caliper and calculated based on the following equation: V = (L
X W 2) / 2, where L is length and W is width of the tumor. Animal experiments were
performed according to the institutional guidelines approved by the University of
Louisville Institutional Animal Care and Use Committee. Survival data were
plotted based on Kaplan-Meier method, followed by the analysis of log-rank test
with SPSS statistical software (version 19.0; SPSS, Inc., Chicago, IL) (172).

Immunohistochemistry. Tumors were harvested one week after the fourth
treatment in vivo, embedded in optimal cutting temperature compound (O.C.T.)
(Sakura Finetek, Torrance Ca), and stored at -20°C. The tumor sections and
immunohistochemical staining were performed as previously reported (173).
Briefly, slides were air-dried, fixed in cold acetone at 4°C for 20 min. The
endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 10
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mins and washed with PBS three times, followed by incubation with SuperBlock
(37515, Pierce Biotechnology, Rockford, IL) at room temperature for 30 min. All
antibodies were applied in SuperBlock. Sections were incubated with
goat-anti-adenovirus polyclonal antibody (AB1056, Millipore, Billerica, MA),
diluted 1:800, for 1 hr at room temperature. The antibody staining signals were
amplified by a biotinylated anti-goat IgG diluted 1:200 in conjunction with
VECTASTAIN avidin-biotin complex method kit (Vector Laboratories, Burlingame,
CA). Visualization was achieved using 3,3-diaminobenzidine tetrahydrochloride
(ImmPACT DAB peroxidase substrate; Vector Laboratories). Slides were
counterstained with hematoxylin and photographed at X200 and X400
magnification and in an Olympus BX53 microscope (Olympus, Center Valley, PA).

Statistical analyses. All above experiments, except specifically indicated, were
repeated at least three times. Quantitation results were reported as means ±
standard deviation (S.D.). Statistical difference of the combination experiment was
assessed with a Student's t-test. Statistical significance of difference was set at p
< 0.05.
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3.3. Results
Ad-cycE induces more significant oncolytic effects on prostate cancer cells
than prostate cancer-specific oncolytic Adhz55. Ad-cycE is an E1b-deleted
vector with the cyclin E promoter to replace the endogenous Ad E1a promoter.
We compared Ad-cycE with Adhz55 which has the prostate cancer-specific
ARR2PB promoter driving Ad E1a gene (167). Non-replicative AdGFP was used
as a negative control, and wild-type Ad 5 (Adwt) was used as the positive virus
replication control. We first examined the E1A expression at 24 hr p.i. in LNCaP
and DU-145 prostate cancer cells. Cells were infected with AdGFP, Adwt, Adhz55
or Ad-cycE at 5MOI. With the same infection condition, the E1A expression of
Ad-cycE was higher than that of Adhz55 in LNCaP and DU-145 prostate cancer
cell lines (Fig. 3.2A, comparing lanes 3 and 4, 7 and 8). We then examined the
cytotoxicity of Adhz55 and Ad-cycE on these two prostate cancer cell lines. Cells
were infected with Adwt, Adhz55, Ad-cycE or AdGFP at 0, 0.5, 1, 2, 4, 8 MOI for
96 hr and the cytotoxicity were determined by crystal violet staining. Figure 3.2B
showed that AdGFP did not induce significant cytotoxicity at different MOIs. Both
LNCaP and DU-145 prostate cell lines were sensitive to Adwt and Ad-cycE
infection, but relatively resistant to Adhz55 (Fig. 3.2).
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Figure 3.2. Comparison of prostate cancer-promoter driven Adhz55 and
cyclin E-promoter driven Ad-cycE in prostate cancer cells. (A) LNCaP and
DU-145 Cells were infected with AdGFP, Adwt, Adhz55 or Ad-cycE at 5 MOI and
collected at 24 hr p.i., respectively. The cell lysates were immunoblotted for E1A
and actin. Actin was used as a loading control. (B) Cells were seeded at a density
of 2 x 104 and infected with Adwt, Adhz55, Ad-cycE or AdGFP at 0, 0.5, 1, 2, 4,
and 8 MOI for 72 hr. Cytotoxicity were determined with crystal violet staining and
photographed. Data are representative examples of three independent sets of
experiments and quantitated as cell viability %. The values represent the means ±
S.D. of independent triplicate compared with the AdGFP-infected group of each
dose.
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Ad-cycE selectively destroys lung cancer cells and spares noncancerous
lung cells. The oncolytic selectivity of Ad-cycE was determined with human A549
lung cancer cells and WI-38 noncancerous lung fibroblast. A549 cell line is a
human lung cancer cell line with dysregulated cyclin E that can be significantly
induced after Ad infection (56); WI-38 cell line has the properties of primary cells
with a finite lifetime of 50 population doublings (174). As we mentioned above,
AdGFP and Adwt were used as a negative and positive replication control,
respectively. As E1b55K-deleted dl1520 with the native E1a promoter can
replicate in different types of cancer cells, we particularly applied it as the
oncolytic Ad control. Cytopathic effects (CPE), the classical characteristic of
oncolytic virus replication, were recorded on Figure 3.3, showing morphological
change as infected cells rounded up and detached from the cell monolayer.
Without replication, AdGFP did not induce CPE on either WI-38 or A549 cells.
Wild-type virus (Adwt) non-selectively induced CPE in both noncancerous WI-38
and A549 lung cancer cells; however Ad-cycE only induced significant CPE on
A549 lung cancer cells but not on WI-38 cells as well as dl1520. In noncancerous
WI-38 cells, Adwt significantly decreased cell viability to 30% (P = 0.0000047,
compared with the AdGFP-infected group), while dl1520 and Ad-cycE do not
cause significant changes (P = 0.28 and 0.2, compared with the AdGFP-infected
group respectively). In A549 cells, Adwt decreased cell viability to 6%, while
dl1520 and Ad-cycE decreased cell viability to 40% and 25%, respectively. It
seems that Ad-cycE can destroy A549 lung cancer cells more efficiently than
dl1520.
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Figure 3.3. Cytopathic effects of human Ads on WI-38 and A549 cells. (A)
Cells were infected with AdGFP, Adwt, dl1520 or Ad-cycE at 8 (for WI-38) or 5
MOI (for A549). CPE was observed at 72 hr p.i and photographed with an inverted
microscope Olympus CKX41. The cell viability % was determined and the values
represent the means ± S.D. of independent triplicate compared with the
AdGFP-infected group.
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Replication of Ad-cycE is activated in cancer cells. Ad E1A is the crucial
protein which initiates the whole virus replication process and promotes cells to
enter S phase (37). With E1a ORF under control of cyclin E promoter, we
hypothesized that E1A transcription in Ad-cycE is activated in cancer cells with
cyclin E overexpression. A549 cells were infected with AdGFP, Adwt, dl1520 or
Ad-cycE at 5 MOI for 24 hr. As Figure 3.4A shown, no E1A expression was
detected in non-replicative AdGFP with the deletion of E1 region whereas the E1A
expression of Ad-cycE was detected in A549 cells at a similar level to dl1520 and
Adwt at 24 hr postinfection (p.i.), suggesting E1A transcription of Ad-cycE is
activated in A549 cells. To determine whether the activation of E1A transcription
leads to Ad-cycE replication, virus production was monitored over time. The data
showed that virus yield of Ad-cycE increased over time as well as Adwt and
dl1520 (from 6.7 X 105 at 0 hr to 8.3 X 108 at 72 hr) (Fig. 3.4B). Taken these data
together, we showed Ad-cycE is a replication-competent virus in A549 lung cancer
cells.
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Figure 3.4. The expression of viral E1A and virus production in A549 cells.
(A) Cells were infected with AdGFP, Adwt, dl1520 or Ad-cycE at 5 MOI and
collected at 24 hr p.i. The cell lysates were immunoblotted for E1A protein and
actin. Actin was used as a loading control. (B) The virus yields were determined at
0, 24, 48, and 72 hr p.i. with the infection unit method. The values represent the
means ± S.D. of independent triplicate.
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Oncolytic efficacy of Ad-cycE on multiple cancer cell lines. To detect the
cytotoxicity of Ad-cycE, human A549 and H1299 lung cancer, MDA-MB-231
breast and Saos 2 osteosarcoma cancer cells were infected with Adwt, dl1520,
Ad-cycE and AdGFP at the indicated MOI for 72-96 hr and stained with crystal
violet (Fig. 3.5). As a positive control, Adwt widely induced strong oncolysis in all
cancer cell lines whereas a non-replicative control AdGFP did not cause oncolysis.
A significant cytotoxicity was observed in all cancer cell lines infected with
oncolytic dl1520 or Ad-cycE when compared to cells infected with non-replicative
AdGFP. Cell viability was then quantified and each group was compared to the
mock-infected group. In Saos 2 osteosarcoma and MDA-MB-231 breast cancer,
Ad-cycE worked even better than dl1520 (Fig. 3.5, Boxed). This experiment
showed that in addition to lung cancer cells, Ad-cycE can efficiently destroy a
variety of cancer cells.
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Figure. 3.5. Cytotoxicity of Ad-cycE in multiple cancer cell types. A549,
H1299, Saos2, and MDA-MB-231 cells were seeded at a density of 2-5 x 104 and
infected with Adwt, dl1520, Ad-cycE or AdGFP at 0, 0.5, 1, 2, 4, and 8 MOI for
72-96 hr. Cytotoxicity were determined with crystal violet staining and
photographed. Data were quantitated as cell viability % values. The quantitated
data of boxed areas indicated that with 2 MOI of virus infection, dl1520 decreased
the cell viability of A549 to 87% while Ad-cycE decreased it to 76%; dl1520
decreased the cell viability of H1299 to 65% while Ad-cycE decreased it to 78%;
dl1520 decreased the cell viability of MDA-MB-231 to 83% while Ad-cycE
decreased it to 59%; dl1520 decreased the cell viability of Saos2 to 92% while
Ad-cycE decreased it to 77%.
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Ad-cycE suppresses tumor growth in athymic nude mice. The therapeutic
effects of Ad-cycE were further examined in the lung cancer subcutaneous
xenograft model. Once palpable tumors were established, the mice were
randomized and 5 × 108 IFU of AdGFP or Ad-cycE in 50 μL PBS was injected
intratumorally every 2 days for total 4 treatments. The tumor sizes of mice were
monitored over the time and the death of mice was recorded. The initial reduction
of tumor volumes in Ad-cycE treated group was observed at day 9 after the first
treatment. Mice treated with Ad-cycE exhibited significant suppression of tumor
growth with 95% reduction in the mean tumor volume as compared with mice
treated with control AdGFP at day 51 after the first treatment (P = 0.0008, Fig.
3.6A). Once the tumor volume exceeded 1000 mm 3, the mouse was sacrificed.
The representative photographs of mice at the day of sacrifice revealed that in
AdGFP-treated groups, tumor kept growing while Ad-cycE treatment suppressed
tumor growth (Fig. 3.6B). In the Ad-cycE-treated group with total seven mice, two
of them were tumor free after the treatment (no longer visible), three had
decreased tumors all the time during the 130 days of follow-up, and two mice had
recurring tumor growth at around 30 days after the first treatment (Fig. 3.6C). In
an additional experiment, tumors from the mice that were injected with AdGFP or
Ad-cycE were harvested 7 days after the last treatment and analyzed with
immunohistochemical analysis to detect hexon protein expression. Hexon
proteins, as the major coat protein of Ad capsids, represent the classic marker of
virus particles (175). Hexon proteins were stained as the brown dots and localized
within the cytoplasm (Fig. 3.6D, panel c and d). The results indicated a higher
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level of hexon expression in the tumor sections generated from A549 cell
xenograft treated with Ad-cycE, suggesting the virus replicated within tumor
tissues. The results reported here clearly demonstrate that Ad-cycE replicates in
tumor tissues and strongly inhibits tumor growth, resulting in prolonged mice
survival and potential antitumor efficacy.
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Figure 3.6. In vivo antitumor effects of Ad-cycE on subcutaneous A549
human lung cancer in nude mice. Mice carrying established A549 tumors were
treated with control virus AdGFP (n=6) or Ad-cycE (n=7) on days 0, 2, 4, and 6.
The total viral dose was 2 x 109 IFU / mouse. (A) The vertical arrow represents
each treatment. Tumor volume (V) was plotted against time and was determined
by the equation V = (L x W 2) / 2, in which L represents the length, and W
represents the width of the tumor. The values represent the means produce ± S.D.
*

P<0.05

compared

with

AdGFP

control

group,

Student’s

t-test.

(B)

Representative mice from each group were photographed at the time of sacrifice.
(C) Kaplan-Meier survival curves were plotted for both treatments (AdGFP n = 6,
Ad-cycE n = 7, P < 0.05, log-rank test). (D) Polyclonal antibody anti-adenoviral
hexon was used to detect the production of adenoviral particles in tissue sections
after treatment. The representative photographs were taken at original
magnification X200 or X400
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3.4. Discussion
One of the significant features of cyclin E is its differential expression in cancer
and normal cells. While dramatic overexpression of cyclin E has been detected in
numerous cancers, the expression levels of cyclin E are repressed in most
nondividing normal cells (87). We previously have shown that cyclin E promoter is
highly active in cancer cells and the promoter activity is further augmented during
viral reproduction process (56, 165). The aim of this study was to evaluate a novel
oncolytic Ad-cycE driven by the human cyclin E promoter with an entire
E1b-deleted backbone. To date, none of known designs of tumor-specific
oncolytic adenovectors took the virus-induced environment into consideration.
This is the first oncolytic adenovector using a human cyclin E promoter combined
with the strategy of entire E1b-deletion. As the replication of Ad-cycE depends on
the activation of cyclin E promoter, the oncolysis of Ad-cycE is enhanced in
cancer cells and repressed in normal cells. Our data showed that Ad-cycE
selectively replicated in multiple cancer cells and inhibited the in vivo tumor
growth in nude mice bearing lung cancers, leading to the prolonged survival time.

Most of the tumor-specific oncolytic adenoviruses are developed based on the
promoters preferentially active in a specific type of cancers (158). Although
regulating the viral gene expression by tumor-specific promoters is feasible, this
approach can be hindered by the relatively weak activity (159-163) or
virus-induced repression (79) on many tumor-specific promoters. Similar
phenomenon was observed when we constructed prostate cancer-specific
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oncolytic Adhz55. We noticed that this kind of tumor-specific promoter somewhat
may not drive E1A expression as well as constitutive viral promoters. Compared
to

prostate

cancer

specific

promoter-based

Adhz55,

human

cyclin

E

promoter-based Ad-cycE elicits better efficacy (Fig. 3.2). Also, the oncolytic
efficacy of Ad-cycE was observed in different type of cancer cells (Fig. 3.5).
Previously we have demonstrated that dl1520 can induce cyclin E overexpression
in the permissive cancer cells that support dl1520 replication but not in the
restrictive cancer cells that are resistant for dl1520 replication (56). Here we
noticed that the oncolysis induced by Ad-cycE is not only restricted in the reported
permissive lung cancer cells A549 and H1299. In the reported restrictive cancer
cells for dl1520 replication, Ad-cycE elicited better oncolytic efficacy than dl1520.
While the exact mechanism(s) to induce oncolysis by Ad-cycE in the restrictive
cancer cells for dl1520 replication remains to be investigated, it is possible that
cyclin E promoter activated after Ad infection may benefit Ad-cycE replication in
those restrictive cancer cells. We have reported that the activity of cyclin E
promoter is enhanced during viral reproduction process (56, 165), and
virus-induced cyclin E activates the cyclin EL-CDK2-pRb/E2F pathway to
enhance cyclin E expression via a loopback regulation (164). We postulate that
oncolytic adenovirus driven by human cyclin E promoter may have a broader
range of application since it can be activated in cancer cells with dysregulated
cyclin E and the promoter activity can be further enhanced by virus reproduction.

The mechanism(s) of Ad-cycE induced oncolysis requires further studies. The
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oncolysis mediated by Ad-cycE may correlate with multiple mechanisms such as
virus replication, apoptosis, and autophagy. The virus replication and release from
cells can directly cause cell lysis as the major mechanism (7, 176). Also, studies
by our laboratory as well studies by others’ have shown that oncolytic Ads with
entire E1b deletion induce more apoptosis compared to E1b55K-deleted dl1520
and wild-type Ad (38, 177). The expression of E1a gene has been shown to
trigger the accumulation of p53 protein, resulting in p53-dependent apoptosis (40,
106). Due to the lack of E1b19K to repress E1A-induced apoptosis, Ad-cycE may
induce more apoptosis than dl1520. Additionally, previously we have shown virus
replication induces autophagy to promote virus replication and oncolysis (166).
Autophagy is a process involving in the lysosomal degradation, recycling of
cellular components and type II programmed cell death (178, 179). Currently we
have studied the mechanism of Ad-cycE-induced oncolysis and are observing
Ad-cycE induced LC3-I to LC3-II cleavage and ATG 5-12 complex formation,
suggesting that this process may also participate in Ad-cycE-induced oncolysis
(Cheng and Zhou, unpublished data).

We extended our findings from in vitro studies to evaluate antitumor effects of
Ad-cycE in a human lung cancer xenograft mouse model, which confirmed the
potent antitumor efficacy elicited by Ad-cycE in vivo. A long-term survival animal
study also allowed us to follow up the responses of individual mice to the Ad-cycE
treatment. The tumors in Ad-cycE-treated mice started shrinking at day 9.
However, during the long-term follow up (over 100 days) we noticed that each
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mouse had individual response to the Ad-cycE treatment. In Ad-cycE-treated
group, two mice had invisible tumor at the end of the study; three mice had
repressed tumor growth all the time; two mice had repressed growth for around 20
days but tumors recurred at around 30 days after the first treatment. It should be
noticed that if virus treatment cannot completely eliminate the tumor mass, the
remnant tumor cells may recur as what may happen in the clinical setting. The
variances among the outbred athymic NCr-nu/nu mice may be one important
determinant for the fates of tumor repression or recurrence. Our observation
pointed out the importance of personalized treatment in the oncolytic virotherapy.
Individual response to oncolytic virotherapy should be taken into consideration to
develop the strategy to achieve better therapeutic outcomes.

In conclusion, in the present study we have shown that human cyclin E promoter
driven Ad-cycE exhibits potent antitumor efficacy in vitro and in vivo. Our study is
the first to demonstrate the application of cyclin E promoter-based vector design
with dual properties to target the cyclin E overexpression in cancer cells and
virus-induced environment. As cyclin E is highly overexpressed in a variety of
cancers and further augmented during virus reproduction, Ad-cycE represents
tumor specificity and potential to overcome restriction in nonpermissive cancer
cells for dl1520. Further studies will help for characterizing the clinical importance
of Ad-cycE in the future cancer treatments.

90

CHAPTER IV
PROPERTIES OF ONCOLYTIC REPLICATION OF ADENOVIRUSES IN
MURINE AND HUMAN LUNG CANCER CELLS

4.1. Introduction
Human adenoviruses (Ads) are double-stranded linear DNA viruses. The viral
genes are divided into early and late genes relative to the onset of viral gene
expression. Ads with deletion of the early E1B55K gene preferentially replicate in
cancer cells and cause oncolysis, leading to the release of amplified and
infectious viruses to further destroy tumor cells (5). Studies by our laboratory as
well studies by others’ have shown that oncolytic Ads can efficiently kill cancer
cells in cell culture and strongly inhibit tumor growth in animal experiments (38,
121, 180, 181). E1b55K-deleted ONYX-015 (dl1520) has been applied in clinical
trials in the United States and H101 (with the similar structure as ONYX-015) has
been commercially approved for cancer therapy in China (17, 18). However, the
antitumor effects of oncolytic Ads have been somewhat disappointing when used
in clinical applications (182, 183).

Current animal models used to evaluate the efficacy of oncolytic Ads rely on
human tumor xenograft in immunodeficient mouse models. However, human
tumor xenograft models are less clinically relevant to the real cancers in patients.
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Human Ads tend to target human tumors and replicate more efficiently in human
cells than in murine cells. Thus preclinical results obtained with human tumor
xenograft in mouse models may overstate the therapeutic efficacy. Additionally,
the lack of functional immune systems in immunodeficient models may hinder the
accuracy of clinically predicting the effects in patients (3, 184). Ads have complex
interactions with host cell immune response effectors (17, 185). In the presence of
the immune system, the oncolytic effects of the virus may be reduced due to the
immune responses against viral particles. Conversely, the immune system may
help the tumor-killing effects by recruiting nature killer cells, antibodies,
tumor-specific cytotoxic T lymphocytes (CTLs) to enhance the therapeutic
outcome (186). Development of immunocompetent mouse models with murine
tumor cells in which oncolytic Ads can selectively replicate is necessary and
important.

Previously we have demonstrated that cyclin E overexpression is a molecular
basis of selective replication of E1b55K-deleted Ads in human cancer cells (56,
79). Ad replication depends on cyclin E induction in cells after Ad infection.
E1b55K-deleted Ads fail to efficiently induce cyclin E expression in the normal
cells, leading to the restricted replication. However, this E1B55K function is not
required in cancer cells which generally already have dysregulated cyclin E;
therefore E1b55K-deleted Ads can successfully replicate in cancer cells and
cause oncolysis. We recently further reported that Ad-induced cyclin E
overexpression adjusts the cellular environment for viral productive replication via
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activating CDK2, that in turn targets the transcriptional repressor pRb and
regulates cell cycle progression (164).

Cyclin E is a nuclear protein essential for the cell cycle progression (80), DNA
replication (110, 111), and centrosome duplication (112, 113). The protein level of
cyclin E rises at late G1 phase and peaks at the G1/S phase to promote S-phase
entry in normal cell cycle (80, 81). Numerous types of cancers are highly
associated with dysregulation of cyclin E, such as cyclin E gene amplification (91),
overexpression of mRNA or protein levels (87, 92), decrease of cyclin E protein
turnover (93, 94), or the presence of more active forms of cyclin E (94-96).
Constitutive overexpression of cyclin E induces chromosome instability (89, 90),
impairs normal cell cycle progression and triggers tumor development in
transgenic animal models (86, 114, 115). Human cyclin E overexpression in
mouse lung leads to development of premalignant and malignant lung lesions
which resemble to the features found in lung cancer patients (88, 115). Murine
ED-1 cell line was derived from the lung cancers of cyclin E transgenic mice (187).
As oncolytic Ad replication is related to dysregulated cyclin E expression, Ads
may selectively replicate in murine ED-1 cancer cells.

Replication of human wild-type Ad5 and oncolytic Ads in murine ED-1 cells was
studied and compared with human lung cancer A549 cells which overexpress
cyclin E. The oncolytic effects of one novel oncolytic Ad-cycE driven by cyclin E
promoter (169) on murine ED-1 lung cancer cells was characterized in this study
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along with dl1520. Our results showed that human Ads can penetrate ED-1 cells
which have the ability to support viral DNA synthesis, early and late gene
expression, and virion production. Although with relatively lower production
compared to in human cells, the pattern of virus replication in murine ED-1 cells is
similar to that in human A549 cells. This study indicates that ED-1 cancer cell line
is permissive for human Ad replication and can be used to develop a new
immunocompetent murine tumor model for evaluating the therapeutic efficacy of
oncolytic Ads.
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4.2. Materials and Methods
Cell lines and culture conditions. HEK 293 (ATCC no. CRL-1573), human lung
cancer A549 (ATCC no. CCL-185) and mouse embryonic fibroblast NIH/3T3
(ATCC no. CRL-1658) cell lines were purchased from the American Type Culture
Collection (Rockville, MD). Murine ED-1 cells line, a lung cancer cell line derived
from transgenic mice with wild-type human cyclin E (88, 187), was a gift from Dr.
Ethan Dmitrovsky and further single-cell subcloned in our laboratory. HEK 293
and A549 cells were cultured in minimal essential medium Alpha. ED-1 cells were
cultured in RPMI-1640 medium. All media were supplemented with 10% fetal
bovine serum (FBS) and penicillin/streptomycin (100 U/ml). Cells were cultured in
a 5% CO2 incubator at 37°C. All cell culture reagents were obtained from Gibco
BRL (Bethesda, MD) and Corning Cellgro (Manassas, VA).

Adenoviral vectors. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1
deletion carrying a green fluorescent protein (GFP), was used as a
replication-defective control. Ad dl1520 is a E1b mutant which contains an 827-bp
deletion and a point mutation to generate a premature stop codon in the E1B55K
coding region (15). Ad-cycE is a novel E1b-deleted oncolytic vector carrying a
human cyclin E promoter driving an intact E1A expression cassette. The
endogenous E1a promoter was deleted and a human cyclin E promoter
(GenBank ID: X95406) was inserted to replace the deleted E1a promoter in
Ad-cycE. Therefore, Ad-cycE contains a human cyclin E promoter to control E1a
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open reading frames (ORF) (169). All of the vectors created and used in this study
are based on the backbone of wild-type Ad type 5.

MTT assay. Cells were seeded into 24-well plates at a density of 2.5 x 104
(cells/well) and cultured under the indicated conditions. Cell proliferation was
assessed at three days after respective treatments by measuring the conversion
of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to
purple formazan, according to the manufacturer's instructions (Boehringer
Mannheim, Indianapolis, IN). The absorbance of the supernatant was measured
at 590 nm using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek, Winooski,
VT). The results were expressed as the fold change relative to the result at day 0.
Doubling time was analyzed from the curves of cell growth in log phase with the
exponential regression analysis provided by http://www.doubling-time.com
(188-190).

Cytotoxicity assay. Cells were seeded into 24-well plates at a density of
2.5 x 104 (cells/well) and cultured under the indicated conditions. Cytotoxicity was
assessed with crystal violet staining (170). Cells were fixed with 3.7%
paraformaldehyde and stained with 1% crystal violet followed by washing with
water to remove excess dye. The dye was solubilized with 2% SDS and the
absorbance of the solubilized stain was measured at 590 nm using a Synergy HT
Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT). The OD values were
quantitated into the cell viability % by the formula, cell viability % = (OD value of
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experimental group / OD value of control group) x 100%. The mock-control group
was calculated as 100% of cell viability in the assay (171).

Southern blot analysis. After viral infection, cells were collected at different time
points. The viral DNA synthesis was determined with Southern blot; 1 µg of
isolated genomic DNA was digested with the restriction enzyme PstI and analyzed
with 1% agarose gel, which was subsequently transblotted to a Hybond-N+
membrane (YA3609; Amersham Pharmacia Biotech, Arlington Heights, IL). The
probe was prepared by digesting 0.5 µg pBHGE3 (122) with PstI and labeled by
following the protocol of Amersham AlkPhos Direct Labeling and Detection
Systems (RPN 3690; GE Healthcare, Piscataway, NJ). The blot was
prehybridized for 3 hrs at 63°C. The hybridization and stringency washes were
performed at 60°C and followed by the chemiluminescent detection according to
the manufacturer’s protocol. Densitometric value for the bands was quantified by
Gel-pro Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) (191) and
expressed as integrated optical density (I.O.D.).

Western blot analysis. Infected cells were harvested at indicated time points and
lysed with CDK2 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl 2,
0.5% Nonidet P-40, 0.1% Brij 35, 5 mM sodium glycerophosphate, 1 mM sodium
vanadate, 1 mM dithiothreitol). The Western blot analyses were performed as
described previously (123). Briefly, 60 µg of cell lysates were electrophoresed
through 12% SDS-polyacrylamide gels and transferred onto an Immobilon-P
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Membrane (Millipore, Billerica, MA). The primary antibodies used in this study
were rabbit anti-cyclin E (M-20), (Santa Cruz Biotechnology, Santa Cruz, CA),
mouse anti-adenovirus type 5 E1A (BD Pharmingen, San Jose, CA), and rabbit
anti-adenovirus type 5 antibody (Abcam, Cambridge, MA). Actin was used as an
internal control. The membranes were then incubated with anti-mouse
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection
was performed with ECL reagents according to the supplier’s recommendations
(GE Healthcare).

Viral titration. Total infected cells and culture supernatants were collected at the
indicated time points and lysed to release virus particles with three cycles of
freezing and thawing. The viral titers were determined by the infective unit method
as described previously (120, 121). Briefly, HEK 293 cells were seeded in 96-well
plates at a density of 103 (cells/well) and then infected with 10-fold serially diluted
viruses. CPE was recorded and scored after incubation for 7 days.

Burst assay. Burst assay were used to determine the replication efficiency of
human Ads in infected cells (192-194). Cells were seeded in 6-well plates at a
density of 2 x 105 (cells/well) for 4 hr and infected with human Ads at 3.5 (for A549
cells) or 10 MOI (for ED-1 cells). At 18 hr postinfection (p.i.) cell supernatants
were removed and the cell monolayers were washed twice with PBS. At 18 hr and
120 hr p.i., cells and supernatants were collected. The viral titers were determined
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by the infective unit method. The burst ratio was expressed as the titer of virus at
120 hr p.i. (virus output) relative to the titer of virus at 18 hr p.i. (virus input). An
increase ratio in virus titer after 120 hours indicates virus replication.

Statistical analyses. All above experiments, except specifically indicated, were
repeated at least three times. Quantitation results were reported as means ±
standard deviation (S.D.). Statistical difference of the combination experiment was
assessed with a Student's t-test. Statistical significance of difference was set at p
< 0.05.

99

4.3. Results
Murine ED-1 cells show higher growth rate and lower serum sensitivity than
human A549 cells. Human A549 and murine ED-1 lung cancer cell lines both
have well-known backgrounds of the cyclin E expression. A549 cell line is the
human lung cancer cell line with constitutive cyclin E expression and has been
reported as a highly permissive cancer cell line for Ad oncolytic replication (56).
ED-1 cell line was derived from transgenic mice with wild-type human cyclin E
expression in lung cancers (88, 187). The growth characteristics of two cell lines
were first compared in this study. Cells were cultured under 10% FBS and the cell
proliferation of the two cell lines were determined by MTT assay. The final number
of ED-1 cells increased 10-fold from day 0 to day 3, while A549 cells increased
5.6-fold when cultured with 10% FBS (Fig. 4.1A). The doubling time generated
from the data of cell growth in log phage indicated that the doubling time of ED-1
cells is 18.6 hr and A549 is 30.17 hr, showing the growth rate of ED-1 cells is
about 1.6-fold greater than that of A549 cells. Growth curves of A549 and ED-1
cells in the presence of serum concentrations ranging from 0% to 10% were
shown in Figure 3.1B. The results showed that proliferation of both cell lines were
repressed under lower serum concentrations. The number of A549 cells cultured
in medium with 0% serum only increased slightly, however ED-1 cells still
managed to increase close to 4 fold under the same conditions (Fig. 4.1B). Thus,
ED-1 cells grow significantly faster and exhibit less sensitivity to the decreased
serum concentration than A549 cells.
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Figure 4.1. Growth characteristics of A549 and ED-1 cells. Cell proliferation
and serum sensitivity of A549 and ED-1 cells were determined by MTT assay at 0,
24, 48 and 72 hr. Cells were seeded into 24-well plates at a density of 2.5 x 104
(cells/well) and cultured in (A) 10% FBS or (B) 0, 0.5, 1, 2.5, 5 and 10% FBS,
respectively. The results were expressed as the fold change relative to the result
at 0 hr. All values represent the means ± S.D. of independent triplicate.
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ED-1 cells require 3-fold higher titers of Ads to achieve similar infection
efficiency as A549 cells. To maintain cells growth under a similar rate and
density, A549 and ED-1 cells were cultured in 1% FBS and 0% FBS, respectively.
Two approaches were applied to evaluate the infection efficiency of human Ads in
A549 and ED-1 cells. First, we evaluated the Ad infection efficiency by quantifying
the number of cells expressing GFP using a vector expressing a GFP reporter
gene (AdGFP). A549 and ED-1 cells were infected with increasing MOI of AdGFP
after seeding for 4 hr. For each infection, three random fields were taken by EVOS
fluorescence microscope (AMG, Bothell, WA) at 72 hr p.i. (Fig. 4.2A). The number
of GFP positive cells and the total cell numbers on each photo were counted with
ImageJ (US National Institutes of Health, Bethesda, MD). The numbers of GFP
positive cells were divided by total cell numbers on each photo to determine the
infection efficiencies and presented in Figure 4.2B. Maximum infection of A549
cells (90%) can be achieved by Ads with an MOI of 10, but ED-1 cells are required
at least an MOI of 20. To have about 60% cell infected, an MOI of 10 is required
for ED-1 cells and an MOI of 2.3 for A549 cells (Fig. 4.2B).
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Figure 4.2. Infection efficiency of human adenoviruses on A549 and ED-1
cells. A549 cells were cultured with 1% FBS and ED-1 cells were cultured with
0% FBS at a density of 105 (cells/well). (A) The photographs were taken by EVOS
fluorescence microscope (AMG, Bothell, WA) at 72 hr p.i. (B) The numbers of
GFP cells on each photo were counted with ImageJ (US National Institutes of
Health, Bethesda, MD). The results were expressed as GFP cell numbers relative
to total cell numbers on the scene. All values represent the means ± S.D. of
independent triplicate.
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Secondly, considering that promoter activity and GFP expression may differ from
cell lines and interfere in determining the infection efficiency, we also used
Southern blot to evaluate the infection efficiency by quantitating the amount of Ad
DNA. As AdGFP is a non-replicative virus, the amounts of AdGFP DNA inside the
cells should represent the amounts of virus DNA that entered into those cells
initially. A549 and ED-1 cells were infected with AdGFP at increasing MOI. Cells
were then harvested at 12 hr p.i. and the total DNA was isolated. The DNA
samples were digested with PstI and then analyzed by Southern blot with Ad DNA
fragments. Figure 4.3A represents the result of human AdGFP DNA entering ED-1
and A549 cells. We observed that with the same MOI of AdGFP infection, Ad DNA
amount entering ED-1 cells was lower than that entering A549 cells. Yet
increasing infection MOI of AdGFP led to a concomitant increase of Ad DNA
amount in both ED-1 and A549 cells, suggesting virus entry can be adjusted by
altering the infection MOI of AdGFP. To compare the concentration of Ad DNA in
ED-1 and A549 cells, we specifically determined the viral DNA densities in ED-1
cells infected with 10 MOI and in A549 cells infected with 2.5, 5 and 10 MOI
(boxed in Fig. 3A). Densitometric values for the bands were quantified by Gel-pro
Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) (191) and expressed
as integrated optical density (I.O.D.) (Fig. 4.3B). The algorithmic result revealed
that to achieve a similar infection with an MOI of 10 AdGFP for ED-1 cells, an MOI
of 3.5 is required for A549 cells. In the following experiments, we chose 3.5 MOI
of human Ad to infect human A549 cells and 10 MOI human Ad to infect murine
ED-1 cells to achieve similar virus infection level for future experiments.
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Figure 4.3. The DNA amounts of AdGFP entering cells. (A) A549 cells were
cultured with 1% FBS and ED-1 cells were cultured with 0% FBS at a density of
106 (cells/well) in 60 mm dishes. Cells were infected with AdGFP at 0, 1.25, 2.5, 5,
10 and 20 MOI, respectively, and harvested at 24 hr p.i.. The DNA isolated from
cells was totally loaded into the agarose gel. The amounts of AdGFP entering
cells were quantitated by analyzing virus DNA amounts in cells with Southern blot.
(B) Densitometric value for the bands was quantified by Gel-pro Analyzer 4.0
software (Media Cybernetics, Bethesda, MD) and presented as integrated optical
density (I.O.D.) values.
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Human oncolytic Ads are able to replicate in both murine and human lung
cancer cell lines but poorly in noncancerous murine cell line. Murine
NIH/3T3 cells generated from NIH Swiss mouse embryo fibroblasts (195) were
applied here as a noncancerous control to compare with murine ED-1 lung cancer
cell line. Relatively high levels of cyclin E expression was detected in human A549
and murine ED-1 lung cancer cells but not in NIH/3T3 cells (Fig. 4.4A). The
cytotoxicity of human Ads on cells were photographed and quantitated. AdGFP
with

deletion

of

E1

region

was

used

as

a

non-replicative

control.

Replication-competent wild-type Ad5 (Adwt) and oncolytic dl1520 (ONYX-015)
and Ad-cycE were chosen to evaluate the human Ad replication. Ad dl1520 is an
attenuated adenovirus with E1b deletion which has been evaluated in several
clinical studies (15, 17). Ad-cycE is an E1b-deleted oncolytic vector carrying a
human cyclin E promoter driving E1A transcription to target lung cancers with
cyclin E overexpression (169). To achieve equal infectivity, human A549 was
mocked-infected or infected with AdGFP, dl1520 and Ad-cycE at 3.5 MOI and
both murine ED-1 and NIH/3T3 cells were infected with various viruses at 10 MOI.
The CPE became visible at 48-72 hr p.i., showing morphological change as
infected cells rounded up and detached from the cell monolayer. Cytotoxicity or
cell CPE caused by Ad infection was photographed with an inverted microscope
(Olympus CKX41) (Fig. 4.4B). Mock-infection and non-replicative AdGFP
infection did not induce cytotoxicity in cells. Adwt induced cytotoxicity in all cell
lines with non-selectivity; however the two oncolytic viruses dl1520 and Ad-cycE
only induced observed cytotoxicity on both A549 and ED-1 lung caner cells but
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not on noncancerous NIH/3T3 cells. Cell viability was determined by crystal violet
staining and then quantified by comparing each group to the mock-infected group
(Fig. 4.4C). The results matched to the observations of virus CPE, suggesting the
selectivity of oncolytic Ads existing in murine cells.
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Figure 4.4. Cyclin E expression and cytopathic effects of human Ads on
human A549, murine ED-1, and NIH/3T3 cells. (A) Cells were seeded in 60 mm
dishes at a density of 106 for 18 hr and then collected. The cell lysates were
immunoblotted for cyclin E protein and actin. Actin was used as a loading control.
(B) Cells were mock-infected or infected with AdGFP, Adwt, dl1520 or Ad-cycE at
3.5 MOI (for A549 cells) or 10 MOI (for ED-1 and NIH/3T3 cells). CPE was
observed at 72 hr p.i and photographed with an inverted microscope Olympus
CKX41. (C) The cell viability % was determined and the values represent the
means ± S.D. of independent triplicate compared with the mock-infected group.
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To determine whether the cytotoxicity was induced by complete virus replication in
murine cells, burst assay was used to compare the virus output with virus input
(192-194). Normally the burst ratio is generated by comparing virus production at
72 hr (final virus output) to 4 hr (initial virus amount entering cells) and an
increased ratio indicates virus replication. Considering human Ad infection for 4 hr
caused very low infection efficiency in murine ED-1 cells, we chose 18 hr as the
initial point and chose 120 hr at which the infected cells showed up complete CPE
as the end point. Yields of Adwt, dl1520 and Ad-cycE increased 756-, 474-, and
269-fold on average after infection in ED-1 cells, respectively. However, Ad titers
only increased 25 fold for Adwt and 2 fold for dl1520 along with Ad-cycE in
NIH/3T3 cells (Fig. 4.5). The burst ratio of Adwt in ED-1 is 30 times greater than
that in NIH/3T3, and the burst ratio of oncolytic Ads were 100-200 fold increase
than that in NIH/3T3, indicating ED-1 is more permissive for human Ad replication
than NIH/3T3.
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Figure. 4.5. Burst ratios of human Ad replication in ED-1 and NIH/3T3 cells.
Cells were infected with Adwt, dl1520, and Ad-cycE at 10MOI for 18 hr or 120 hr.
The virus yields were determine by infection unit method and expressed as burst
ratios, representing virus yields at 120 hr p.i. relative to virus yields at 18 hr p.i..
The values represent the means ± S.D. of independent triplicate.
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Wild-type and oncolytic human Ads replicate in both human and murine
lung cancer cells. To further characterize the properties of human Ad replication
in A549 and ED-1 cells, Ad DNA synthesis, E1A expression, the production of viral
capsid proteins and the virus yields were analyzed. The viral DNA synthesis of
human Ad was determined by Southern blot with the probes of Ad genomic DNA.
As shown in Figure 4.6, mock-infected group did not contain viral DNA and the
viral DNA level of non-replicative AdGFP was not detectable on the blot. Only in
replication-competent Ad groups we detected viral DNA level which continuously
increased from 24 hr to 48 hr p.i.. The results showed that Adwt, dl1520 and
Ad-cycE can replicate in both human and murine lung cancer cells; oncolytic
Ad-cycE can achieve the similar level as dl1520. The viral DNA synthesis level in
ED-1 is lower than that in A549.
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Figure. 4.6. Human Ad DNA synthesis in A549 and ED-1 cells. Virus DNA
synthesis was determined by Southern blot. 3.5 MOI was used to infect A549 cells
and 10MOI was used to infect ED-1 cells to achieve the similar infection efficiency.
The DNA was isolated from the cells at 24 and 48 hr p.i. and fragmented with the
restriction enzyme PstI. The probe was Adwt genome DNA.
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The E1A expression level was examined by Western blot at 24 hr p.i. E1A is the
crucial protein which is expressed immediately after infection and initiates the
virus replication cycle (37). Ad E1A protein expression was examined at 24 hr and
identified as multiple bands in the range of 35-46 kDa generated from the
alternative splicing of E1A transcripts (196). As the pattern shown in human A549
cells and murine ED1 cells, Ad E1A expression was only detected in the groups
infected with replication-competent Adwt, dl1520 and Ad-cycE, but not in the
groups mock-infected or infected with non-replicative AdGFP carrying the deletion
of E1 region (Fig. 4.7A).

The capsid protein production of human Ads in A549 and ED-1 was shown in
Figure 4.7B. Consistent to the pattern of E1A expression, capsid protein
production at 72 hr was detected in both human and murine cancer cells infected
with replication-complete Adwt, dl1520 and Ad-cycE. To determine the virus
production in both cell lines, virus yields were determined by the infection unit
method and monitored over the time. Figure 4.7C revealed that virus yields of
human Ads in murine ED-1 cells and human A549 cells increased over the time;
the overall virus yield in ED-1 cells was 10-fold lower than that in human A549
cells. The titers of Adwt, dl1520 and Ad-cycE produced by A549 cell culture at 72
hr after infection increased to the range between 108 and 109 (IFU/ml); while the
virus titers produced by ED-1 were between 107 and 108 (IFU/ml) (Fig. 4.7C).
Taken all data together, we demonstrated that wild-type and oncolytic dl1520 and
Ad-cycE can replicate in both human A549 and murine ED-1 lung cancer cells.
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Figure 4.7. The expression of viral E1A, capsid protein and virus production
in A549 and ED-1 cells. (A) Cells were mock-infected or infected with AdGFP,
Adwt, dl1520 or Ad-cycE at 3.5 MOI (for A549 cells) or 10 MOI (for ED-1). Cells
were collected at 24 hr p.i. and the cell lysates were immunoblotted for E1A
protein and actin. (B) Infected cells were collected at 72 hr and the cell lysates
were immunoblotted for viral capsid protein and actin. Actin was used as a loading
control. (C) The virus yields were determined at 0, 24, 48, and 72 hr p.i. with the
infection unit method. The values represent the means ± S.D. of independent
triplicate.
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4.4. Discussion
Adenovirus-mediated oncolysis is a novel approach for cancer therapy. Current
animal experiments rely on immunodeficient mouse models with human xenograft
tumors to evaluate the efficacy of oncolytic Ads. Due to the species specificity,
human Ads tend to infect and replicate in human tumors rather than in murine
tissues. Thus preclinical results obtained with human tumor xenografts in
immunodeficient mouse models may overstate the therapeutic effects of oncolytic
Ads. In addition, the patient’s immune responses may inhibit or augment oncolytic
therapy. In this study, we compared Ad replication in murine and human lung
cancer cells. We found that human Ads can penetrate and replicate in both
murine and human lung cancer cells. When murine and human cancer cells are
equally infected, viral DNA synthesis, early and late gene expression and virion
production are observed with similar effects in both human and murine cells.
Although with a lower production compared to human cells, human Ads can
selectively replicate in and destroy murine cancer cells.

Murine cells require a higher MOI of Ads to achieve same level infection as with
human cancer cells. Entry of Ads into cells includes two well-known steps. The
first step initiates from the high-affinity binding of adenovirus fiber knob to the
coxsackievirus and adenovirus receptor (CAR) (197-200), followed by secondary
interaction of the penton base with cell surface integrins to mediate the
internalization of virus (201, 202). Human CAR is a transmembrane protein
belonging to the immunoglobulin superfamily (203). The primary amino acid
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sequences of human and murine CARs are highly homologous (203), thus the
murine CAR may function as the key receptor for human Ad to enter murine cells.
Besides murine CAR, cell surface integrins may be the other mediator for human
Ad entry into the murine cells. Integrins are a family of cell-surface receptors for
adhesion to extracellular matrix proteins or counter receptors on other cells (204).
The RGD motif of the human Ad penton base serves as a recognition site for
several human cellular integrins including αvβ3, αvβ5, αvβ1 andα3β1 (197,
201, 204, 205). Studies have shown that some murine integrins share high
homology with human integrins (206, 207). Additionally, heparan sulphate
glycosaminoglycans (HS-GAGs) may play an important role in the cross-species
infection of human Ad on murine cells. HS-GAGs have been shown to mediate
CAR-independent attachment and infection by human Ads 2 and 5 in previous
reports (208, 209). The basic motif of Lys-Lys-Thr-Lys (KKTK) on human Ad fiber
shaft near the penton base was found to bind HS-GAGs (197, 210, 211). Raman
et al. indicated that instead of murine CAR, mouse adenovirus type 1 utilizes
cellular αv integrin and HS-GAGs as the primary receptors to enter murine cells
(211). The infection of human Ads on murine ED-1 cells can be mediated via the
known murine CAR, coreceptors such as integrins and heparan sulfate
glycosaminoglycans or even by the other unknown pathways.

Determinants of human Ad replication are also related to other steps of interaction
with host cells. Once the human Ad particles are internalized into cells, viral
replication in murine ED-1 lung cancer cells proceeds as in human A549 lung
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cancer cells. We also compared human Ad replication in murine cancer cells and
in noncancerous murine NIH/3T3 cells. Oncolytic Ads virions were produced at
high levels in cancer ED-1 cells, but not in NIH/3T3 cells. Obviously, the entire
human Ad life cycle can be completed in murine ED-1 lung cancer cells, but it is
repressed in NIH/3T3 cells. It has been reported that human Ads normally
undergo abortive replication but still can cause cell lysis in murine cells (212, 213).
Virus yields of Ad2 and Ad5 in 3T3-Swiss and BALB/c 3T3 cells were reduced 3 to
5 logs compared to virus production in human cells (214, 215), and no infectious
virus particles of Ad12 were detected in murine 3T3 (embryo) and L (connective
tissue) cells (213, 216). The block of human Ad replication in murine cells may be
related to the low infectivity, unstable and reduced DNA synthesis, abortive
expression of late proteins or the defective assembly and maturation at an later
stage of viral replication cycle (213-218). Similar phenomenon was observed
when we studied the human Ad replication in Chinese hamster ovary (CHO) cells.
Even though we continuously observed that human wild-type Ad induces
cytotoxicity on CHO cells, lack of late protein production appears to prevent
infectious virion production in CHO cells (Cheng and Zhou, unpublished data).
Our study shows that murine cancer ED-1 cells, but not noncancerous NIH/3T3,
have the properties to allow human Ads to complete reproduction steps.

While the exact mechanism(s) supporting the complete reproduction process of
human Ads in murine cancer ED-1 cells remains to be investigated, it is tempting
to speculate that the human cyclin E overexpression in the cell line may play an
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important role. Cyclin E expression in murine ED-1 cells may support the virus
reproduction process on multiple ways. Under the normal condition, cyclin E
regulates cell cycle progression, DNA replication licensing (110, 111, 219),
centrosome duplication (112, 113) and E2F activation (85). We previously
demonstrated that human Ad replication relies on cyclin E induction by Ad
E1B55K (56). Ad-induced cyclin E turns on the pRb/E2F pathways by activating
CDK2 (164). It is possible that human Ad replication in murine ED-1 cells can be
enhanced by cyclin E overexpression and/or any of cell proliferation alterations
occurring in the carcinogenesis caused by the cyclin E overexpression. Potentially,
ED-1 cells may be important to clarify the factors altered by cyclin E
overexpression that allow cross-species replication of human Ads.

In this report, we have shown that oncolytic Ads can selectively replicate in and
destroy murine ED-1 cancer cells derived from the mouse lung adenocarcinomas.
Currently we have inoculated FVB mice with ED-1 cells and are observing the
formation of syngeneic mouse tumors in the animals. This study indicates that
with murine cancer cells permissive for oncolytic Ad replication, it is feasible to
establish syngeneic and immunocompetent mouse tumor models for preclinical
studies that will better evaluate the anticancer effects of oncolytic Ads and predict
therapeutic outcome in the clinical setting.
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CHAPTER V
COMBINATION OF AUTOPHAGY INDUCER RAPAMYCIN AND ONCOLYTIC
ADENOVIRUS IMPROVES ANTITUMOR EFFECT IN CANCER CELLS

5.1. Introduction
Oncolytic virotherapy with E1b55K-deleted adenoviruses (Ads) has been applied
to human clinical trials in the United States and approved for the commercial use
in China (18, 27, 32, 180, 220). The selective oncolytic effects can be achieved by
a small quantity of viruses that spread to surrounding tumor cells, therefore
contributing to an interesting drug platform (4, 153). Considering the viral tropism,
respiratory oncolytic Ads should have a high potential for lung cancer therapy
(221). However, lung cancer is generally difficult to treat with oncolytic viruses,
and there are few recorded successful trials due to the cancer’s propensity to
metastasize and the irregular shape of most tumors. Therefore, developing
combination strategies to target human lung cancer with improved oncolytic Ads
would allow for more effective treatment.

In clinical treatments, oncolytic Ads are generally used with the first-line
chemotherapy drugs, and the combination treatments have exhibited high
therapeutic efficiency and improved safety (222). However, the interaction
mechanism between chemotherapy drugs and viruses has not been well charac-
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terized. Selecting drugs for combination therapies based on the understanding of
the interaction between Ads and drugs definitely will benefit the feasibility of this
strategy. In our previous study, we have shown that the treatment of the
autophagy inducer rapamycin increased the Ad yields and the autophagy inhibitor
3-methyladenine (3-MA) reduced Ad replication (166). Our studies have also
shown that autophagy may generate decomposed cellular molecules as nutrition
to support Ad replication. Thus, an autophagy inducer may improve virus oncolytic
therapy.

Autophagy is a process involving the lysosomal degradation and recycling of
cellular proteins and cytoplasmic organelles (178). Environment stressors such as
nutrient starvation and pathogen infection induce autophagy. Autophagy initiates
from membrane structures called phagophores (178, 223, 224), which engulf
cellular and cytoplasmic components, followed by elongation and recruitment of
microtubule-associated protein 1 light chanin 3 (LC3) to form the characteristic
double-membrane autophagosome. Cytoplasmic form LC3-I and lipidated form
LC3-II are two forms of LC3 post-transcriptionally produced in cells (225-227).
LC3 is immediately processed into LC3-I after synthesis. During the autophagy
process, LC3-I is cleaved by cysteine protease Atg4 to generate lipidated form
LC3-II that localizes on autophagosome membranes (224, 228). The amount of
LC3-II or the LC3-II/LC3-I ratio can be used to estimate the degree of
autophagosome formation (225, 226, 229). Autophagosomes eventually fuse into
lysosomes to form autolysosomes, in which the inner components undergo the
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degradation process and produce amino acids and fatty acids for reuse in cells.
Rapamycin, the inhibitor of the mammalian target of rapamycin (mTOR) (230,
231), has been shown to induce autophagy and inhibit proliferation of malignant
glioma cells (232). Autophagy is negatively regulated by the PI3K-AKT-mTOR
pathway. Via inhibiting the negative regulation of mTOR signaling, rapamycin
indirectly enhances autophagy.

Using a tumor-specific promoter to regulate Ad E1A expression is a general effort
to control selective replication of vectors in cancer cells and cause oncolysis. The
proteins encoded by the E1a region, expressed immediately after infection, then
modulate the cell cycle, recruit cellular proteins, and produce viral proteins to
process viral DNA replication (37). However, all known tumor-specific promoters
are relative weak compared with the native promoter of the Ad E1a gene (159,
161). In addition, Ad infection can cause strong repression of most cellular
promoters, as indicated in our published microarray study (79). Vectors driven by
tumor-specific promoters generally elicit low potency and do not work as
efficiently as dl1520, which contains the native E1a promoter and is applied in
current tumor treatments (159, 161). However, the native E1a promoter does not
exhibit selectivity and therefore has side effects, such as virus replication in
noncancerous cells (155, 156). Obviously, the selection of promoters in vector
construction should consider the negative effects imposed by virus infection on
those promoters. We thus have constructed a novel E1b-deleted oncolytic
Ad-cycE, in which Ad E1a gene is driven by the cyclin E promoter. Cyclin E is
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known to regulate DNA replication and promote the S-phase entry (110, 111).
Cyclin E overexpression is frequently detected in many types of cancers,
including lung cancer (87). Recent studies also showed that overexpression of
cyclin E can trigger lung cancers in transgenic mice (86, 115). Our previous
studies revealed that the replication of E1b55K-deleted Ads is significantly
repressed in G0-arrested normal cells (56, 123), in which the cyclin E promoter is
restricted. We have also demonstrated that the activity of cyclin E promoter in
cancer cells is further augmented after Ad infection (56, 165). As the replication of
E1b-deleted Ad-cycE depends on the activation of cyclin E promoter, Ad-cycE
replication may be enhanced in cancer cells and repressed in normal cells.

In this study, we applied novel tumor-specific Ad-cycE and rapamycin in
combination to enhance oncolytic effects. We show that Ad-cycE is competent to
replicate in human lung cancer cells but not in the normal lung cells and that the
combination of oncolytic Ad-cycE and the autophagy inducer rapamycin elicits
synergistic inhibition effects. We also reveal that rapamycin increases Ad E1A
expression and virus production. Our studies have clearly shown that autophagy
inducers as chemotherapeutic agents are capable of increasing adenoviral
replication and oncolysis. Thus the combination of autophagy-associated
chemotherapy and oncolytic virotherapy may be a new approach to improve
future cancer treatment.
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5.2. Materials and Methods
Cell lines and culture conditions. HEK 293 (ATCC no. CRL-1573), WI-38
human lung fibroblast (ATCC no. CCL-75), MCF10A human mammary epithelial
(ATCC no. CRL-10317), MDA-MB-231 human breast cancer (ATCC no. HTB-26),
A549 (ATCC no. CCL-185) and H1299 (ATCC no. CRL-5803) human lung cancer
cell lines were purchased from the American Type Culture Collection (Rockville,
MD). WI-38 human lung fibroblast cell line has the properties of primary cells with
a finite lifetime of 50 population doublings (174). MCF10A human mammary
epithelial cell line is an immortalized but non-transformed human breast epithelial
cell line (233, 234). WI-38 cells were cultured in minimal essential medium (MEM)
Alpha GlutaMAX with 0.1 mM non-essential amino acids and 1.0 mM sodium
pyruvate. MCF10A cells were cultured in DMEM/F12K with 20ng/ml EGF,
0.5μg/ml Hydrocortisone, and 10μg/ml insulin. HEK 293, A549 and MDA-MB-231
cells were cultured in DMEM. All media were supplemented with 5% (for MCF10A
cells)

or

10%

(for

the

other

cells)

fetal

bovine

serum

(FBS)

and

penicillin/streptomycin (100 U/ml). Cells were cultured in a 5% CO2 incubator at
37°C. All cell culture reagents were obtained from Gibco BRL (Bethesda, MD).

Adenoviral vectors. Figure 5.1 depicts the structures of the adenoviruses
applied in this study. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1
deletion carrying a green fluorescent protein (GFP), was used as a
replication-defective control (164). Ad-cycE is a novel E1b-deleted oncolytic
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vector carrying a human cyclin E promoter driving an intact E1A expression
cassette. The endogenous E1a promoter was deleted and a human cyclin E
promoter (GenBank ID: X95406 (168)) was inserted to replace the deleted E1a
promoter in Ad-cycE. Therefore, Ad-cycE contains a human cyclin E promoter to
control E1a open reading frames (ORF). The details of Ad-cycE construction will
be reported separately in our preparing report. All of the vectors created and used
in this study are based on the backbone of wild-type Ad type 5.
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Figure 5.1. Structure of the Ads. The wild-type Ad (Adwt) with the E1a and E1b
genes and their endogenous promoters is shown at the top. The left inverted
terminal repeat (ITR), the promoters for E1a gene and E1b genes (E1a-P and
E1b-P) and the E1a and E1b open reading frames are indicated. The solid lines
represent Adwt regions in these viruses, and the dashed lines represent the
deleted regions. AdGFP contains the complete deletion of E1a and E1b regions
and their promoters. Ad-cycE contains the deletion of E1b region and a cyclin E
promoter (cycE-P) was inserted to replace the deleted E1a promoter.
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Cytotoxicity assay. Cells were seeded into 24-well plates at a density of
2.5 x 104 (cells/well) and cultured under the indicated conditions. After 72 hours,
Cytotoxicity was assessed with crystal violet staining (170). Cells were fixed and
stained with 1% crystal violet followed by washing with water to remove excess
dye. The dye was solubilized with 2% SDS and the absorbance of the solubilized
stain was measured at 590 nm using a Synergy HT Multi-Mode Microplate Reader
(Bio-Tek, Winooski, VT). The OD values were quantitated into the cell viability %
by the formula, cell viability % = (OD value of experimental group / OD value of
control group) x 100%. Rapamycin and viruses were diluted with corresponding
culture media. The 0 nM control group was treated with the diluents and was
calculated as 100% of cell viability in the assay (171).

Analyses of combination effects of rapamycin and Ad-cycE. In this study, an
additive effect refers to a combined effect of drugs that produces the sum of their
individual effects; synergism is the combined effect of drugs which is greater than
the sum of individual effects, and antagonism is the combined effect of drugs
which is less than the sum of individual effects (235, 236). The combined effects
of rapamycin and Ad-cycE on cell viability were analyzed with the median-effect
methods of Chou and Talalay (237) using CalcuSyn software (Biosoft, Ferguson,
MO). The combination index (CI) values were used to evaluate the interaction
between the drug and virus. For the fraction of virus affected combination index
(Fa-CI) plot analysis, a CI < 1 is defined as synergism, a CI = 1 is defined as an
additive effect, and a CI > 1 is defined as antagonism. The data were confirmed
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with the isobologram method (238, 239). The diagonal curves connecting the xand y-axes were calculated from single treatments to represent the additive effect
for the theoretical combinations of two treatments at the specific effective doses. If
the data points fall on the lower left of the diagonal, the combination is regarded
as synergism. If the experimental data points of the drug combination fall on the
diagonal, the combination is regarded as an additive effect. If the data points fall
on the upper right of the diagonal, the combination is regarded as antagonism.

Viral titration. Cells were seeded into 6-well plates at a density of 2 x 105
(cells/well) and treated under the indicated conditions. Total infected cells and
culture supernatants were collected at 48 hr postinfection (p.i.) and lysed to
release virus particles with three cycles of freezing and thawing. The viral yields
were determined by the infective unit method as described previously (120, 121).
HEK 293 cells were seeded in 96-well plates at a density of 103 (cells/well) and
then infected with 10-fold serially diluted viruses. CPE was recorded and scored
after incubation for 7 days.

Western blot analysis. Cells were harvested and lysed with CDK2 lysis buffer
(20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.5% Nonidet P-40, 0.1% Brij 35,
5 mM sodium glycerophosphate, 1 mM sodium vanadate, 1 mM dithiothreitol).
The Western blot analyses were performed as described previously (123). 25 µg
of cell lysates were electrophoresed through 10 or 12% SDS-polyacrylamide gels
and transferred onto an Immobilon-P Membrane (Millipore, Billerica, MA). The
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primary antibodies used in this study were rabbit anti-LC3 and actin (Sigma, St.
Louis, MO), mouse anti-adenovirus type 5 E1A (BD Pharmingen, San Jose, CA),
and rabbit anti-adenovirus type 5 antibody (Abcam, Cambridge, MA). Actin was
used as an internal control. The membranes were then incubated with anti-mouse
immunoglobulin G (IgG) or anti-rabbit IgG peroxidase-linked species-specific
whole antibody (GE Healthcare, Piscataway, NJ). Chemiluminescent detection
was performed with ECL reagents according to the supplier’s recommendations
(GE Healthcare). The scanned band intensity was quantitated by Gel-pro
Analyzer 4.0 software (Media Cybernetics, Bethesda, MD) according to the
manufacturer’s tutorial. Densitometric value for each band was expressed as
integrated optical density (I.O.D.) and normalized with actin. The results were
reported as the ratios of normalized band intensities of LC3-II to LC3-I.

Statistical analyses. All above experiments, except specifically indicated, were
repeated at least three times. Quantitation results were reported as means ±
standard deviation (S.D.). The Pearson correlation coefficient (r) was used to
evaluate the correlations between the rapamycin concentrations and cell viability
percentages by SAS software, Version 9.3 (SAS Institute Inc., Cary, NC) (240,
241). Statistical difference of the combination experiment was assessed with a
Student's t-test. Statistical significance of difference was set at p < 0.05.
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5.3. Results
Selective replication of Ad-cycE in cancer cells. Figure 5.1 depicts the
structures of the adenoviruses applied in this study. Adwt was used as a
replication-competent control. AdCMV/GFP, a vector with E1a and E1b deletion
carrying a green fluorescent protein (GFP), was used as a replication-defective
control. Our previous reports indicated that the cyclin E promoter is more active in
lung cancer cells than in normal lung cells and oncolytic E1b-deleted Ad infection
further elevates the promoter activation (56, 165). Thus, we replaced the native
E1a promoter with the cyclin E promoter to generate Ad-cycE, a novel
E1b-deleted oncolytic vector.

To determine the selectivity of Ad-cycE for cancer cells, we first examined the
cytotoxicity of Ad-cycE on normal and cancer cell lines. WI-38 human lung
fibroblast, MCF10A mammary epithelial, A549 and H1299 lung cancer and
MDA-MB-231 breast cancer cells were infected with AdGFP, Adwt or Ad-cycE at 5
MOI. Ad-cycE replicated in A549 and H1299 human lung cancer, and
MDA-MB-231 breast cancer cells and caused cytopathic effect (CPE) similar to
that of Adwt (Fig. 5.2A, comparing panel hr and i, k and l, n and o). The CPE
became visible at 48 hr and 72 hr p.i., showing that the infected cells became
circular

and

detached

from

the

cell

monolayer.

Unlike

Adwt,

which

indistinguishably induced CPE in noncancerous WI-38 human lung fibroblast and
MCF10A mammary epithelial cells, Ad-cycE selectively induced CPE in all tested
cancer cells (Fig. 5.2A, comparing panel b and c, e and f).
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WI-38, A549 and H1299 cells were infected with Adwt or Ad-cycE at 5 MOI and
the total infected cells and culture supernatants were collected at 72 hr to
examine the production of infectious virus particles. Figure 5.2B revealed that in
noncancerous WI-38 human lung fibroblast cells, the virus yield of Adwt was
significantly higher than that of Ad-cycE (P = 0.04); in H1299 human lung cancer
cells, there was no significant difference between the virus yield of Adwt and
Ad-cycE (P = 0.2); in A549 human lung cancer cells, Adwt (3.7 X 109) and
Ad-cycE (8.3 X 108) achieved a high level of virus yield, indicating the replication
property of Ad-cycE in lung cancer cells. The aggregated data from this
experiment shows that Ad-cycE can selectively replicate in and efficiently destroy
cancer cells but poorly replicates in noncancerous cells.
Previous studies indicate that replication-competent oncolytic Ads could produce
the essential Ad E1 proteins to support the replication of replication-defective
E1-deleted Ads co-transduced in vitro or in vivo (165, 242, 243). To further verify
selective replication capability of Ad-cycE in cancer cells, A549 human lung
cancer cell line with constitutive cyclin E production (56) was chosen for the
following experiment. A549 cells were infected with 5MOI AdGFP alone, or
AdGFP

plus

an

additional

Ad

(AdGFP+AdlacZ,

AdGFP+Adwt

or

AdGFP+Ad-cycE). Figure 5.2C showed that the non-replicative AdGFP
maintained the original level of infectivity at day 1 and day 2 (compare panels a
and b). Also, with coinfection of AdGFP and non-replicative AdlacZ, the
fluorescent cell numbers did not change (compare panels c and d). Yet with the
addition of Adwt (compare panels e and f) or Ad-cycE (compare panels g and h),
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we detected an increase of fluorescent cell numbers from day 1 to day 2,
suggesting that efficacy of Ad-cycE replication in cancer cells is comparable with
the wild-type Ad.
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Figure 5.2. Selective oncolytic replication of Ad-cycE. (A) WI-38, MCF10A,
A549, H1299 and MDA-MB-231 cells were infected with AdGFP, Adwt, or Ad-cycE
at 5 MOI. CPE was observed at 48 hr or 72 hr p.i and photographed with an
inverted microscope Olympus CKX41. (B) Viral yields produced in WI-38, H1299
and A549 cells were determined at 72 hr p.i. with the infection unit method. The
values represent the means ± S.D. of independent triplicate. * P<0.05, Student’s
t-test. (C) A549 cells were co-infected with 5 MOI AdGFP and mock-infection,
AdlacZ, Adwt or Ad-cycE. All fluorescent microscopy is taken at day 1 and day 2
p.i. with an Olympus IX50 microscope (original magnification of X100).
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Rapamycin induces autophagy and inhibits lung cancer cell growth.
Rapamycin has been shown to induce autophagy and inhibit proliferation of
malignant glioma cells (232). We investigated whether rapamycin can induce
autophagy in A549 lung cancer cells. The cells were treated with 0 nM, 100 nM,
and 200 nM rapamycin for 24 hr. Western blot was used to determine the
conversion of LC3-I to LC3-II, which is one of the representative characteristics of
autophagy activation. LC3 is immediately processed into LC3-I after synthesis.
Then the cytoplasmic form LC3-I is cleaved by cysteine protease Atg4 to generate
lipidated form LC3-II that specifically localizes to autophagosome membranes
(228). Thus the amount of LC3-II or the LC3-II/LC3-I ratio can be applied to
estimate the abundance of autophagosomes (225, 226, 229). Figure 5.3A shows
two forms of LC3, the upper band corresponding to LC3-I and lower band
corresponding to LC3-II (225). Compared with the 0 nM-control group (the ratio of
LC3-II/LC3-I = 0.82), the 100 nM and 200 nM rapamycin treatments increased the
amount of LC3-II and caused the ratio of LC3-II/LC3-I to 2.75 and 2.88,
respectively, indicating the induction of autophagy. Next we examined the effect of
rapamycin on A549 cell growth. The cells were treated with 0 nM, 100 nM, 200 nM,
400 nM, 600 nM and 800 nM rapamycin for 72 hr. The cell viability was
determined with crystal violet staining and quantitated into cell viability
percentages. The results showed that rapamycin decreased cell viability in a
dose-dependent manner at 72 hr compared to the 0 nM-control group (r =
-0.69033, P = 0.0002) (Fig. 5.3B).
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Figure 5.3. Effects of rapamycin on cytotoxicity and autophagy. A549 cells
were treated with 0 nM, 100 nM, and 200 nM ramamycin (LC Laboratories,
Woburn, MA) and collected at 24 hr after treatment. (A) Cell lysates were
immunoblotted for LC3 and actin. Actin was used as a loading control. The values
indicate the ratios of normalized band intensities of LC3-II to LC3-I. (B) A549 cells
were treated with 0 nM, 100 nM, 200 nM, 400 nM, 600 nM and 800 nM ramamycin.
The cell viability % was determined at 72 hr after treatment. The values of cell
viability % represent the means ± S.D. of independent quadruplicate compared
with the 0 nM-control group.
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Combination of rapamycin and Ad-cycE elicits stronger cytotoxicity than
single treatment alone. We first chose 200 nM rapamycin as the working
condition and tested the combination effects of rapamycin with different MOIs of
Ad-cycE on lung cancer cell growth. Figure 5.4A shows a difference between the
cell viability percentage of treatment with Ad-cycE alone and Ad-cycE in
combination with rapamycin. Our results show that Ad-cycE in combination with
rapamycin induces greater CPE in A549 lung cancer cells than either treatment
alone. The distinction can be clearly seen in both 0.5 MOI Ad-cycE and 1 MOI
Ad-cycE. Statistical Student's t-tests confirmed the significant difference.
Treatments with 200 nM rapamycin or 1 MOI Ad-cycE both resulted in the cell
viability of about 50% (53.9% for rapamycin and 52% for Ad-cycE). Combination
of Ad-cycE and rapamycin decreased cell viability to 23.6% (P = 0.00000011). We
repeated the experiment with even lower dose of Ad-cycE (0.5 MOI), which only is
able to induce slight CPE. 0.5MOI Ad-cycE only caused 73.9% of the cell viability
(P = 0.0052), but combination with 200 nM rapamycin caused 39.4% of the cell
viability (P = 0.0000000002). The cell morphology was photographed with an
inverted microscope on day 2 (Fig 5.4B). These results suggest that rapamycin in
combination with Ad-cycE elicits greater cytotoxicity on A549 cells even with a low
MOI of Ad-cycE.
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Figure 5.4. Effects of combination of rapamycin and Ad-cycE on A549 cells.
A549 cells were non-treated or treated with 200 nM rapamycin alone, 0.5 or 1
MOI Ad-cycE alone, or the combination treatment of 200 nM rapamycin and 0.5 or
1 MOI Ad-cycE. (A) The results were quantitated into cell viability %. The values
of cell viability % represent the means ± S.D. of independent triplicate compared
with the mock-control group. * P<0.05, Student’s t-test. (B) CPE was
photographed at a magnification of X100 at 48 hr p.i.
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Rapamycin increases Ad E1A expression and oncolytic replication. The
stronger antitumor effect in the combination treatment may be generated from the
sum of the effect of two individual treatments or even a synergistic effect (one
treatment may increase the efficacy of the other). To understand the mechanism
by which rapamycin in combination with Ad-cycE caused stronger antitumor
effects, we first examined the production of virus particles, comparing virus alone
with the combination groups. Rapamycin treatment led to a 4.25-fold increase in
virus yield compared to the virus alone group (Fig. 5.5A). This suggests that
rapamycin increases the production of Ad-cycE in A549 cells, resulting in stronger
antitumor effects than either drug or virus alone. Next we examined the E1A
expression to determine the mechanism by which rapamycin may contribute to
the increased production of Ad vectors. E1A is the crucial protein which is
expressed immediately after infection and initiates the virus replication cycle (37).
Ad E1A protein expression was examined at 18 hours and identified as multiple
bands at 35-46 kDa generated from the alternative splicing of E1A transcripts
(196). As shown in Figure 5.5B, rapamycin stimulates elevated E1A expression in
the combination group when compared to Ad-cycE alone. Taken together, the
results suggest that rapamycin increases oncolytic replication of Ad-cycE in A549
cells and enhances E1A expression.
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Figure 5.5. Effects of rapamycin on the oncolytic replication of Ad-cycE.
A549 cells were non-treated or treated with 200 nM rapamycin alone, 0.5 MOI
Ad-cycE alone, combination treatment of 200 nM rapamycin and 0.5 MOI Ad-cycE.
(A) Viral yields were determined at 48 hr p.i. with the infection unit method. The
values represent the means ± S.D. of independent triplicate. (B) Cell lysates
harvested at 18 hr p.i. were immunoblotted for Ad E1A and actin. Actin was used
as a loading control.
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Combination of rapamycin and Ad-cycE elicits synergistic antitumor effects.
To determine whether combination of rapamycin and Ad-cycE produce synergistic
antitumor effects, we evaluated the combination treatments with Calcusyn (Biosoft,
Ferguson, MO). The combination experiment was performed by adopting the
constant ratio drug combination design proposed by Chou and Talalay (237).
A549 human lung cancer cells were treated with rapamycin alone (from 100 nM to
700 nM), Ad-cycE alone (from 0.5 MOI to 3.5 MOI) or a combination of rapamycin
(nM) with Ad-cycE (MOI) at the constant ratio of 200:1 for 96 hr. Concordant with
the results shown in Figure 5.4, combination of rapamycin and Ad-cycE caused a
greater cytotoxicity than either treatment alone (Fig. 5.6A). We then evaluated
these quantitated data by fraction affected versus combination index (Fa-Cl) with
CalcuSyn software (Biosoft, Ferguson, MO) (Fig. 5.6B). The X-marks represent
the combination index (CI) values of the combination treatment groups. The CI
values are 0.326, 0.512, 0.506, 0.642, and 0.689 for 100 nM rapamycin plus 0.5
MOI Ad-cycE, 200 nM rapamycin plus 1 MOI Ad-cycE, 300 nM rapamycin plus 1.5
MOI Ad-cycE, 600 nM rapamycin plus 3 MOI Ad-cycE, and 700 nM rapamycin
plus 3.5 MOI Ad-cycE, respectively. The middle curve line represents the
simulated combination index values of the combination treatment groups
surrounded by two lines of algebraic estimations of the 95% confidence intervals.
All experimental CI values at the tested ratio were significantly < 1 and between
the two confidence lines, indicating synergism of combination treatments.

Since rapamycin and Ad treatments have entirely independent modes of action,
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the conservative isobologram method (237, 244) was also applied here to confirm
the above Fa-Cl results. The effective concentration EC50, EC75 and EC90 refer to
the concentration of a drug or the combination of the two drugs that induces 50%,
75% and 90% inhibition of cell viability (236). Figure 5.6C shows the conservative
isobologram plots of EC50, EC75 and EC90, separately. In the conservative
isobologram plot, the curve connecting each axis indicates the simulated additive
effect for EC50, EC75 and EC90, respectively. The experimental EC50, EC75 and
EC90 doses of the combination treatment groups are displayed as the single point
indicated by the arrow. The point values of the EC50, EC75 and EC90 for the
combination treatments all fall below their diagonal lines for simulated additive
effects, indicating that significantly lower doses of rapamycin and Ad-cycE are
therapeutically effective when combined. For example, in EC50 isobologram, from
the simulated curve of the additive effect it shows that to reach 50% inhibition of
cell viability requires at least 800 nM rapamycin or 1 MOI Ad-cycE. However, with
the combination of rapamycin and Ad-cycE it takes a relatively low dose (50 nM
rapamycin plus 0.25 MOI Ad-cycE) to achieve the same efficacy, suggesting
combination treatment elicits a greater effect (synergism) than an additive effect.
These results in Figure 5.6A, B and C have all demonstrated that the combination
of rapamycin with Ad-cycE elicits a synergistic antitumor effect in A549 human
lung cancer cells at the tested concentration ratio.
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Figure 5.6. Analysis by Calcusyn (Biosoft, Ferguson, MO) of the interaction
between rapamycin and Ad-cycE on A549 cells. Cells were treated with
rapamycin alone, Ad-cycE alone or combination of both for 96 hr. (A) The results
were quantitated into cell viability %. The values of cell viability % represent the
means ± S.D. of independent triplicate compared with the mock-control group. (B)
The quantitated cell viability data were analyzed by CalcuSyn software. The
X-marks represent the combination index (CI) values of the combination
treatment groups. The middle curve line represents the simulated combination
index values of the combination treatment groups surrounded by two lines of
algebraic estimations of the 95% confidence intervals. (C) The effective
concentration EC50, EC75 and EC90 refer to the concentration of a drug or
combination of drugs that induces 50%, 75% and 90% inhibition of cell viability. In
the conservative isobologram plot, the three curves of the expected EC50, EC75
and EC90 additive effect lines for the combination treatments are labeled; the
individual points of EC50, EC75 and EC90 for the combination treatments were
indicted by arrows and located below their additive interaction lines, respectively.
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In addition, we examined the combination effect of rapamycin and Ad-cycE on
MDA-MB-231 human breast cancer cell line, which has been reported as a
non-permissive cancer cell line for oncolytic Ads replication (56). As we observed
in A549 cells, the combination of rapamycin and Ad-cycE induced a greater
cytotoxicity than either treatment alone in MDA-MB-231 cells (Fig. 5.7A) and the
therapeutic effect was significantly enhanced by the synergism of combination
treatments (Fig. 5.7B).
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Figure 5.7. Effects of combination of rapamycin and Ad-cycE on
MDA-MB-231 cells. (A) Cells were treated with rapamycin alone, Ad-cycE alone
or combination of both for 96 hr. The results were quantitated into cell viability %.
The values of cell viability % represent the means ± S.D. of independent triplicate
compared with the mock-control group. (B) The quantitated cell viability data were
analyzed by CalcuSyn software. In the fraction affected versus combination index
(Fa-CI) plot, all experimental CI values at the tested ratio were significantly < 1
and within the confidence lines.
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To determine whether the findings with rapamycin and oncolytic Ad-cycE may
apply to wild-type Ad, we tested the same conditions with the combination of
rapamycin and Adwt. Consistent to the results shown in Figure 5.6 and 5.7,
combination of rapamycin and Adwt also caused a greater cytotoxicity than either
treatment alone (Fig. 5.8A). Fa-Cl plot showed that all CI values at the tested
concentration ratio were significantly < 1 and between the two confidence lines,
suggesting the synergism of rapamycin and Adwt (Fig. 5.8B). Our data indicated
that the synergism is not only observed in the combination of rapamycin and
oncolytic Ad-cycE but also in that of rapamycin and Adwt, suggesting the potential
of applying rapamycin to the strategy of combination treatment with the other
oncolytic Ads.
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Figure 5.8. Effects of combination of rapamycin and wild-type Ad on A549
cells. (A) Cells were treated with rapamycin alone, Adwt alone or combination of
both for 72 hr. The results were quantitated into cell viability %. The values of cell
viability % represent the means ± S.D. of independent triplicate compared with the
mock-control group. (B) The quantitated cell viability data were analyzed by
CalcuSyn software. In the fraction affected versus combination index (Fa-CI) plot,
all experimental CI values at the tested ratio were significantly < 1 and within the
confidence lines.

149

5.4. Discussion
Oncolytic virotherapy has shown promising therapeutic results and is considered
a potential approach for cancer therapy (245). The matchless advantage of this
approach is that selective oncolytic effects are initiated by a small amount of
viruses that spread to the surrounding regions until all cancer cells are destroyed
(4). However, due to the current limitations, virus replication and diffusion are
restricted in animal studies and clinical trials when the objectives carry tumors
with large masses (17, 121, 246). Viruses have difficulty penetrating massive
tumors; this may be a reason for disappointing therapeutic outcomes. Developing
new strategies to increase virus propagation in tumors is important in improving
the efficiency of oncolytic virotherapy.

In our previous study we have shown that autophagy may generate decomposed
cellular molecules as nutrients to support virus replication (166). Therefore we
applied the autophagy inducer rapamycin to develop a combination strategy with
oncolytic Ad-cycE. First, rapamycin-caused autophagy can generate more
nutrients that can be used for building the viral particles (166, 247). Second,
autophagy may increase virus particle release from dead cells that may benefit
viral spread in tumors (248). Third, rapamycin has been applied to transplant
recipients as an immunosuppressant to prevent organ rejection (249). The
immunosuppressive properties of rapamycin mainly result from the inhibition of
leukocyte

activity

and

cytokine

expression.

Thus,

rapamycin

as

an

immunosuppressant may help virus to decrease host antiviral responses and
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improve virus distribution in tumors. Finally, autophagy-induced cell death has
been applied as the new target in chemotherapy (250). Thus the antitumor effects
can be enhanced by both rapamycin-caused autophagy and virus-mediated
oncolysis.

We demonstrated that Ad-cycE selectively replicated in cancer cells. Ad-cycE in
combination with autophagy-inducer rapamycin further induced synergistic
antitumor effects. Rapamycin may also improve oncolytic therapy mediated by
other viruses. Studies have shown that an autophagy mechanism is required for
hepatitis B virus replication (251), the initiation of hepatitis C virus replication (252)
and the promotion of viral replication of the RNA viruses such as poliovirus and
rhinovirus (253). The new role of autophagy to help the virions of adenovirus type
2 (Ad2) to traffic in cells has also been discovered in a recent study (247). After
the virus has been internalized into cells, high level of autophagosomes induced
by autophagy are reported to fuse with the early endosomes containing virions
and form amphisomes, creating an environment favoring the release of virions
into cytosol. Here, we specifically observed that the autophagy inducer rapamycin
increased the E1A expression and led to higher Ad-cycE production. In
agreement

with

our

finding,

Zeng

and

Carlin

(2013)

reported

that

starvation-induced autophagy enhanced the E1A expression and the viral
progeny production of Ad2 in human airway epithelial cells (247). E1A is the
crucial protein expressed immediately after infection and regulates the expression
of multiple cellular and viral genes to initiate the virus replication cycle (37).
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Therefore, we reasoned that autophagy is not only able to generate nutrients for
building viral particles, but is also able to increase the E1A expression of Ads,
leading to higher virus production and the enhanced combination therapeutic
effects.

mTOR pathway has been considered as a determinant regulator in the cellular
metabolism (254). The mTOR inhibitor rapamycin has been reported to elicit
diverse and paradoxical effects on the cellular metabolism. Some studies
suggested that rapamycin decreases glucose metabolism (255-257) and
mitochondrial oxidative functions in mammalian cells (258, 259), whereas some
others

suggested

that

rapamycin

increases

glycolysis

and

oxidative

phosphorylation in the targeted cells (260, 261). Fang et al. (2013) pointed out
that although detrimental metabolic changes were observed at early stages of
rapamycin treatment in mice, the prolonged rapamycin treatment leaded to
beneficial metabolic alterations, including increased insulin sensitivity, improved
lipid profile and metabolism (262). Apparently, the discrepancy of those metabolic
alternations by rapamycin likely depends on the natures of signaling pathways
activated in the cell lines and the duration of treatment (261, 262). Under this
circumstance, the relation between the metabolic alterations induced by mTOR
inhibition and the adenoviral replication still remains unclear. Some DNA viruses
such as adenovirus and human cytomegalovirus stimulate metabolic alternations
such as glycolysis in the host cells to generate energy and essential elements for
viral replication (263-265). Besides autophagy, the property of rapamycin to
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induce metabolic changes may be also utilized by adenovirus to create a
beneficial environment for the viral replication.

Based on our previous work with the chemical CDK2 inhibitor roscovitine (164),
we noticed that some chemotherapeutic agents with the kinase inhibition
properties may inhibit oncolytic Ad replication and thus impair the outcome of
oncolytic virotherapy in the combination therapy. It is important to select the
chemotherapeutic agents without negative effects on oncolytic viruses when
conducting the combination therapy. mTOR regulates several essential signal
transduction pathways including the control of cell-cycle progression (254). As an
mTOR inhibitor, one of the key functions of rapamycin is to inhibit cell-cycle
progression (266). Rapamycin is reported to decrease cyclin D1 expression (267),
reduce the kinase activity of cyclin D1/CDK4 and cyclin E/CDK2 complexes (268),
and block the elimination of the CDK inhibitor p27 (269), leading to cell cycle
arrest in G1-S-phase (266). The mechanism(s) by which oncolytic adenoviruses
overcome the cell cycle arrest by rapamycin-induced mTOR inhibition requires the
further study. Considering the possible negative effects of rapamycin on cell
cyclins and cell-cycle progression, autophagy is likely to conduct a very important
role for the rapamycin-enhanced virus replication in this study.

Our studies suggest a novel strategy involving targeting cyclin E overexpression
in cancer cells and the properties of autophagy to enhance adenoviral oncolysis
that could have a significant impact on clinical outcomes in cancer therapy. The
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combination of Ad-cycE and rapamycin can be further tested in vivo to evaluate
the efficacy and efficiency for the clinical setting. Our findings also provide
important information for future adenoviral vector development and the
combination study for improving oncolytic virotherapy.

154

CHAPTER VI
SUMMARY AND FUTURE PERSPECTIVES

Although E1b55K-deleted oncolytic Ads has been applied in many clinical trials
and marketed for cancer therapies in China, the mechanism enabling tumor
selectivity of the viruses still remains controversial. The lack of understanding of
selective replication of E1b55K-deleted Ads limits further development of the
oncolytic virotherapy in cancer patients. Our goal is to fill these gaps and to obtain
valuable information to benefit virotherapy. Previously we have demonstrated that
cyclin E plays a critical role in adenovirus replication and deregulation of cyclin E
expression in cancer cells is the molecular basis of selective replication of the
oncolytic Ads. In this dissertation we further develop the mechanism model and
extended the knowledge achieved from this model to the virtual application in the
design of a novel tumor-specific oncolytic Ad.

Initial studies, shown in Chapter II, have demonstrated the role of cyclin E
participates in oncolytic Ad replication through activation of CDK2; generating a
suitable environment for viral replication. Ad E1B55K mediates cyclin E induction
for viruses to efficiently replicate in normal cells. This E1B55K function is not
critically required for the viral replication in cancer cells due to the deregulated
cyclin E expression or having E1B55K-like cancer cellular factors, thus allowing
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preferential replication of E1b55K-deleted Ads in cancer cells. Ad-induced cyclin
E binds to and activates CDK2 that subsequently phosphorylates the
transcriptional suppressor pRb, which can regulate expression of multiple cellular
and viral genes, including cyclin E itself. (The work has been published in PLoS
ONE 8(2): e57340.)

The work presented in Chapter III focuses on characterization of the replication
profile of oncolytic virus Ad-cycE in human lung cancer cells. Cyclin E promoter is
highly active in cancer cells and its activity is further enhanced after Ad infection.
We utilized the dual properties of cyclin E promoter and have constructed a novel
E1b-deleted Ad-cycE in which Ad E1A is driven by human cyclin E promoter as a
novel therapeutic agent. Ad-cycE exhibits potent antitumor efficacy in vitro and in
vivo and thus prolongs the survival time of mice bearing lung cancer xenograft. As
cyclin E is highly deregulated in numerous cancers and further augmented during
virus multiplication, oncolytic Ad-cycE represents tumor specificity and has the
possibility to overcome restriction in nonpermissive cancer cells for dl1520. (The
manuscript is in preparation.)

In Chapter IV, we extended our studies from human lung cancer cells to evaluate
the oncolytic efficacy of Ad-cycE with murine lung cancer cells. Our data showed
that Ad-cycE can selectively replicate in and destroy murine ED-1 cancer cells
derived from the mouse lung adenocarcinomas. Thus ED-1 is identified as a
permissive murine lung cancer cell line for oncolytic Ad replication. We have
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evaluated the oncolytic efficacy of Ad-cycE with the syngeneic ED-1 mouse
tumors in the immunocompetent FVB mice. (The manuscript is in preparation.)

As shown in Chapter V, the impact of combination treatment with Ad-cycE and
rapamycin which induces autophagy in lung cancer was explored based on the
hypothesis that autophagy enhances oncolytic replication of Ad-cycE. Ad-cycE in
combination with autophagy-inducer rapamycin has been shown to induce
synergistic antitumor effects. Our data suggest this strategy involving in targeting
cyclin E overexpression in cancer cells and enhanced autophagy could have a
significant impact on clinical outcomes in cancer therapy. (The work has been
published in Virology Journal 10(1):293)

The work presented in this dissertation has addressed the question, “By which
mechanism does cyclin E contribute to oncolytic viral replication in cancer cells?”
and revealed the potential of Ad-cycE for clinical application. Our work also raises
a number of interesting directions for future research in the field of oncolytic
virotherapy.

First, cancer cells with cyclin E deregulation may provide E1B55K-like factors to
allow the cyclin E induction by E1b55K-deleted oncolytic Ads to overcome the
growth restriction; however what kinds of cancer cellular factors existing in
permissive cancer cells for this function are still unclear. Future study can focus
on identifying the E1B55K-like factors existing in cancer cells and characterizing

157

the following application to improve oncolytic virotherapy.

Second, our studies in the novel oncolytic Ad driven by cyclin E promoter have
illuminated an attractive potential for this approach with dual properties to target
both cancer tumorigenesis and virus-induced intracellular environment change.
Transcriptionally controlling viral genes or other therapeutic genes with the human
cyclin E promoter can be expected as feasible. Future vectors may combine this
strategy with the other strategies, such as genetic modification on viral fibers or
arming the virus with cytokine or anticancer genes. The new-generation tumor
specific adenoviruses, with enhanced transduction efficiency and immunity
stimulation, may increase cancer killing effects and improve therapeutic outcomes
from oncolytic virotherapy.

Third, we have identified a novel permissive murine lung cancer cell line for
oncolytic

Ad

replication.

A

future

orthotopic

lung

cancer

model

in

immunocompetent syngeneic mouse model should be developed using these
murine lung cancer cells to better evaluate oncolytic virotherapy in a more
patient-like setting and study the role of immune responses in oncolytic
virotherapy. Further preclinical studies on pharmacodynamics, pharmacokinetics
and the toxicity of oncolytic Ads with rodent and non-rodent models should also
be investigated before Ad-cycE and the other similar Ad vectors can be applied to
human clinical trials.
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Additionally, we observed the synergistic antitumor effects elicited by applying
combination strategy with novel Ad-cycE and an autophagy inducer rapamycin in
vitro. The future in vivo studies should be included to evaluate the benefit for
clinical application. Another area of the field that bears further attention is to
identify more potent autophagy inducers rather than only using the prototype drug
rapamycin for this combination strategy. A screening test of combination effects of
oncolytic Ads with novel autophagy inducers such as Spermidine (270),
Saikosaponin-d (271) and GTM-1 (272) can be designed and conducted to select
more efficient candidates to achieve improved outcomes. We believe that the
future progression in oncolytic adenovirology, along with various improvements in
therapeutic strategies should pave the way for the next wave of oncolytic
virotherapy.
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APPENDIX
List of Abbreviations
3-MA

3-methyladenine

Ad

adenovirus

Adwt

wild-type adenovirus

ATG

autophagy-related protein

BCL-2

B-cell lymphoma 2

CPE

cytopathic effect

CDC25

cell division cycle 25

CDK2

cyclin-dependent kinase 2

CHO

Chinese hamster ovary

CAR

coxsackievirus and adenovirus receptor

cyclin EL

large form of cyclin E

CLS

centrosomal localization signal

CTLs

cytotoxic T lymphocytes

CI

combination index

DNA

deoxyribonucleic acid

DMSO

dimethyl sulfoxide

EC

effective concentration

FBS

fetal bovine serum

Fa-CI

fraction of virus affected combination index
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GFP

green fluorescent protein

hTERT

human telomerase reverse transcriptase

HS-GAGs

heparan sulphate glycosaminoglycans

IP

immunoprecipitation

IFU

infectious unit

IgG

immunoglobulin G

I.O.D

integrated optical density

ITR

inverted terminal repeat

LC3

microtubule-associated protein 1 light chanin 3

MDM2

mouse double minute 2 homolog

mRNA

messenger ribonucleic acid

MCM

minichromosome maintenance protein

MLP

major late promoter

mTOR

mammalian target of rapamycin

MOI

multiplicity of infection

MEM-Alpha

minimal essential medium Alpha

ORF

open reading frame

OD

optical density

PBS

phosphate buffered saline

Rb

retinoblastoma gene

pRb

retinoblastoma protein

phospho-pRb

phosphorylated pRb

PCNA

proliferating cell nuclear antigen

177

p.i.

post infection

PSA

prostate-specific antigen

Ros

roscovitine

siRNA

small interfering ribonucleic acid

S.D.

standard deviation

SDS

sodium dodecyl sulfate
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